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 i 
Thesis Summary 
Chapter 1 presents a literature review, focused primarily on the pathophysiology and 
management of atrial fibrillation (AF).  
Chapter 2 examines correlations between the dominant frequency of AF - calculated 
using principal component analysis from a modified surface 12-lead ECG (which 
included posterior leads), a standard 12-lead ECG and intracardiac recordings from both 
atria.  The inclusion of posterior leads did not improve correlation with left atrial 
activity because of the dominance of lead V1 in both ECG configurations. 
Chapter 3 explores whether acute and 12-month outcome following catheter ablation for 
AF can be predicted beforehand from clinical and surface AF waveform parameters.  
Multivariate risk scores combining these parameters can predict arrhythmia outcome 
following ablation, and could therefore be used to identify those most likely to benefit 
from this therapy. 
Chapter 4 examines the effect of catheter ablation on AF symptoms and quality of life 
(QoL).  AF symptom and QoL scores improved significantly in patients who 
maintained sinus rhythm after ablation but did not change in those with recurrent AF.  
AF-specific QoL scales are more responsive to change and correlate better with ablation 
outcome. 
Chapter 5 examines inter-atrial frequency gradients in patients with persistent AF using 
multipolar contact mapping.   A right-to-left atrial frequency gradient was found in a 
quarter of the patients studied, implying that their arrhythmia was being maintained by 
high frequency sources in the right rather than the left atrium. 
Chapter 6 examines whether targeting high frequency and highly repetitive complex 
fractionated atrial electrogram sites, identified using multipolar contact mapping during 
persistent AF, resulted in arrhythmia termination and maintenance of sinus rhythm 
long-term.  The utility of administering flecainide to distinguish critical from bystander 
AF sites was also investigated.  Flecainide did not help refine ablation targets and 12-
month outcome after targeting these sites was not superior to other ablation strategies. 
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Chapter 1. Introduction: Atrial Fibrillation 
1.1  Definition 
Atrial fibrillation (AF) is a 
supraventricular tachyarrhythmia 
characterised by rapid, chaotic 
electrical activity in the atria that 
results in an irregular and frequently 
uncontrolled ventricular rate.  On the 
surface ECG, AF is characterised by 
the replacement of regular distinct P 
waves by fibrillatory waves of varying amplitude and cycle length associated with an 
irregular ventricular rate (Figure 1.1).  Patients can be asymptomatic or can experience 
symptoms including chest pain, palpitations, dyspnoea, fatigue and dizziness. 
1.2 Classification 
AF can be classified into five categories based on the clinical presentation and duration 
of the arrhythmia (Camm et al., 2010): 
1. First diagnosed: Patients who present with AF for the first time are considered in 
this category, irrespective of arrhythmia duration and symptoms. 
2. Paroxysmal: AF episodes that self terminate within 7 days. 
3. Persistent: AF episodes last longer than 7 days and require termination by either 
pharmacological or electrical cardioversion. 
4. Long-standing Persistent: AF has lasted for ≥ 1 year when it has been decided to 
adopt a rhythm control strategy. 
5. Permanent: The continuing presence of AF has been accepted and a rate control 
strategy has been chosen. 
1.3 Epidemiology 
AF is the most common sustained cardiac arrhythmia encountered in clinical practice 
and affects 1-2% of the general population.  In Scotland, a national epidemiological 
survey of 362,155 patients between April 2001 and March 2002 found that the overall 
prevalence of AF was 8.7 per 1000 people (9.4/1000 in men and 7.9/1000 in women) 
and that the prevalence increased with age from 0.3/1000 <45 years to 30.5/1000 in 65-
74 years and more than doubling to 70.7/1000 in patients >85 years.  The incidence of 
AF was 0.9-1/1000 in men and 0.8/1000 in women (Murphy et al., 2007). 
Figure 1.1: 12 lead ECG showing Atrial Fibrillation  
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1.4 Aetiology 
There are many risk factors for the development of AF (Table 1.1): 
 
Table 1.1: Risk factors for AF 
In the Framingham study, the development of AF was associated with increasing age 
(odds ratio (OR) 2.1 for men and 2.2 for women), diabetes mellitus (OR 1.4 men; 1.6 
women), hypertension (OR 1.5 men; 1.4 women) and valvular heart disease (OR 1.8 
men; 3.4 women) (Benjamin et al., 1994).  Several dietary and lifestyle factors have 
also been associated with AF including excessive alcohol (Mukamal et al., 2005) and 
caffeine consumption and emotional and physical stress.  AF can also develop in a 
subset of patients ≤ 60 years of age with no clear aetiology and in the absence of overt 
cardiopulmonary disease – ‘lone AF’.  The true prevalence of lone AF is unknown, 
varying between 1.6% and 30%, depending on the patients’ age and inclusion/exclusion 
criteria used in the study (Brand et al., 1985; Kopecky et al., 1987; Scardi et al., 1999). 
1.5 Prognosis 
The natural history of AF is marred by serious complications, of which stroke is the 
most debilitating.  AF is associated with a prothrombotic state on account of intra-atrial 
blood stasis, structural abnormalities in the fibrillating atria and generalised 
hypercoagulability (Lip, 1995).  Coexisting medical conditions such as hypertension 
and diabetes also increase the risk of stroke.  The rate of ischaemic stroke among 
patients with non-valvular AF is on average 5% per year, which is 2 to 7 times greater 
than in patients in sinus rhythm (Wolf et al., 1991; AF Investigators, 1994).  One in 
every six strokes occurs in a patient with AF (Hart and Halperin, 1999).   
Cardiac Non-Cardiac 
Hypertension Chronic lung disease 
Valvular heart disease (especially mitral 
pathology) 
Pulmonary embolism 
Cardiomyopathy Sepsis  
Post cardiac surgery (inflammation) Thyrotoxicosis 
Coronary artery disease Electrolyte disturbance 
Sick sinus syndrome Diabetes mellitus 
Pericardial disease Obstructive sleep apnoea (Gami et al., 2007) 
Congenital heart disease Chronic kidney disease 
Atrial septal defect and myxoma Obesity (Wanahita et al., 2008) and 
Metabolic Syndrome (Watanabe et al., 2008) 
 Drugs 
 Genetic factors 
 Endurance athletes (Molina et al., 2008) 
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Figure 1.2: Atrial Action Potential 
Phase 0: Depolarisation 
Phase 1: Early repolarisation 
Phase 2: Plateau 
Phase 3: Terminal repolarisation 
Phase 4: Resting membrane potential 
In the Framingham Study, stroke risk was increased 17-fold in patients with rheumatic 
heart disease and AF compared with age-matched controls (Wolf et al., 1978) and the 
risk was five times greater than in patients with non-rheumatic AF (Wolf et al., 1991).  
The risk of stroke also increases with age with an annual risk of stroke attributable to 
AF of 1.5% in patients aged 50-59 years and 23.5% in patients aged 80-89 years (Wolf 
et al., 1991).   
Multiple cohort studies describe an independent association between AF and mortality.  
The mechanism by which AF confers this independent mortality risk is not completely 
understood; nevertheless, AF is associated with an odds ratio for death of 1.5 in men 
and 1.9 in women, which does not vary with age (Benjamin et al., 1998).  Cardiac 
failure is another well-recognised complication of AF and is associated with increased 
mortality.  In addition, the structural and haemodynamic consequences of cardiac failure 
can result in the development of AF due to loss of atrial transport function and 
tachycardia-induced cardiomyopathy (Wang et al., 2003; Nerheim et al., 2004).  
Patients with AF also have a significantly poorer quality of life and reduced exercise 
capacity when compared to patients in sinus rhythm (Thrall et al., 2006) and can 
experience cognitive impairment due to recurrent cardioembolic events in the absence 
of an overt stroke (Knecht et al., 2008). 
1.6 Arrhythmia Mechanisms 
1.6.1 Atrial Electrophysiology 
The resting membrane potential of atrial 
cardiomyocytes is set by the inwardly 
rectifying potassium current IK1 to a value 
close to -80mV.  When an impulse is 
conducted from the sinoatrial node, the 
cell is depolarised by the opening of 
voltage-gated sodium channels causing an 
action potential (Figure 1.2).   
Depolarisation also triggers the entry of 
calcium through L-type Ca2+ channels, 
which generates the action potential 
plateau and causes calcium release from 
intracellular stores in the sarcoplasmic reticulum resulting in myocardial contraction.  
Repolarisation is governed by a variety of potassium currents, which return the 
cardiomyocyte to its resting membrane potential thereby restoring cellular excitability.  
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The electrophysiological 
mechanisms underlying cardiac 
arrhythmias are illustrated in 
Figure 1.3. 
1.6.2 Enhanced Automaticity 
Enhanced atrial automaticity is 
caused by an increase in 
depolarising Na+ or Ca2+ inward 
currents or a decrease in 
repolarising K+ outward currents, 
which results in progressive cell 
depolarisation.  When the threshold 
potential is reached, the cell 
produces an action potential, 
which, if it occurs before the next 
sinus beat, results in ectopic atrial 
activation.  If the slope of diastolic 
depolarisation is increased, for 
example by acute myocardial 
ischaemia, the cell will reach threshold earlier and generate ectopic action potentials at a 
faster rate than the sinus node. 
1.6.3 Early and Delayed Afterdepolarisations 
Delayed afterdepolarisations (DADs) are the most important mechanism of focal 
cardiac arrhythmias.  They result from abnormal diastolic leak of Ca2+ from the 
sarcoplasmic reticulum into the cytoplasm.  Excess diastolic Ca2+ is handled by the cell 
membrane Na+/Ca2+ exchanger which transports three Na+ ions into the cell for every 
Ca2+ ion expelled creating a net depolarising current that produces DADs.  When DADs 
become large enough to reach threshold potential, they cause ectopic firing, either as a 
single beat or as a sustained tachycardia.   
Early afterdepolarisations are caused by a depolarising inward Ca2+ current which arises 
in cells with prolonged action potential duration.  They, in turn, can cause neighbouring 
cells with normal repolarisation to reach threshold earlier causing ectopic firing. 
  
Figure 1.3: Focal Arrhythmia Mechanisms  
Adapted with permission from Wakili et al. (2011). 
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1.6.4 Reentry 
Reentry arises from variable impulse 
propagation through different zones of tissue 
(Figure 1.4).  In normal tissue (top panel), an 
electrical impulse arriving at an area of 
conduction block (pink triangle) will split and 
travel down each side of the obstruction (1&2) 
and the impulses that meet below the 
obstruction will cancel each other out. 
Reentry (bottom panel) can occur if pathway 2 
has unidirectional block therefore allowing 
impulses to travel retrogradely but not in an 
antegrade direction.  An impulse travelling 
down pathway 1 will travel around the 
obstruction (pathway 3) and then travel 
retrogradely through the area of unidirectional 
block in pathway 2.  Within this grey area, 
conduction velocity is reduced due to recent 
depolarisation.  When the impulse exits the grey area, it can reenter pathway 1 if the 
tissue is excitable and a continuous reentrant circuit is formed.   
Reentry requires appropriate tissue properties including a conduction barrier, 
unidirectional block within a conduction pathway, critical timing (normally initiated by 
an ectopic beat) and duration of effective refractory period.  Shortening of the action 
potential duration and therefore refractory period facilitates reentry due to earlier 
recovery of excitability allowing the reentrant impulse to sustain itself throughout the 
circuit.  Similarly, slowed conduction can facilitate reentry by allowing more time for 
cells to recover excitability before the reentrant impulse arrives. 
  
Figure 1.4: Reentry (see text) 
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1.7 Pathophysiological Mechanisms 
The framework for 
understanding the mechanisms of 
AF is based largely on ideas 
developed in the early 20th 
century (Garrey, 1924).  The 
principal competing theories at 
the time were that AF is caused 
by: (1) Rapidly discharging atrial 
ectopic foci, (2) Single circuit 
reentry, and (3) Multiple wavelet 
reentry (Figure 1.5). 
1.7.1 Focal Ectopic Activity 
A focal mechanism of AF was 
initially supported by 
experimental models of aconitine 
and pacing-induced AF in which the arrhythmia was only maintained in isolated areas 
of atrial myocardium (Scherf et al., 1948 and 1953).  This theory received little attention 
until the landmark observation by Haissaguerre and colleagues in 1994 that AF is often 
triggered by a focal source and that ablation of that focal trigger can eliminate AF 
(Haissaguerre et al., 1994; Jais et al., 1997; Haissaguerre et al., 1998).  While the 
pulmonary veins are the most frequent source of these rapidly firing ectopic foci, they 
have also been found in the posterior wall of the left atrium, coronary sinus, ligament of 
Marshall, superior vena cava and crista terminalis (Tsai et al., 2000; Lin et al., 2003; 
Schmitt et al., 2002).  The importance of the pulmonary veins in triggering and 
maintaining AF led to a detailed investigation of their anatomical and 
electrophysiological properties.  There is now general agreement that myocardial 
muscle fibres extend from the left atrium into the pulmonary veins for between 1 and 
3cm (Weiss et al., 2002) and that these fibres contain specialised conduction tissue with 
pacemaker activity (Jongbloed et al., 2004).  Other studies have shown that the 
pulmonary veins and pulmonary vein-left atrial junction are also preferential sites for 
local re-entry with signal fractionation, decremental conduction and shorter action 
potential duration compared to the body of the left atrium (Jais et al., 2002).  This 
heterogeneity of conduction provides the ideal substrate for local reentry, which can 
maintain AF after initiation by an appropriate trigger. 
Figure 1.5: Pathophysiological Mechanisms 
Reproduced with permission from Wakili et al. (2011). 
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1.7.2 Single Circuit Reentry and Rotors 
Schuessler et al. (1992) demonstrated that increasing concentrations of acetylcholine in 
an isolated canine right atrium converted multiple reentrant circuits to a single, 
relatively stable, high frequency reentrant circuit that resulted in fibrillatory conduction.  
Subsequent advances in the understanding of 
reentrant arrhythmias have led to the concept of 
‘rotors’, which occur when a wavefront 
destabilises after colliding with a functional or 
anatomical obstacle, giving rise to vortices of 
electrical spiral waves and turbulent electrical 
activity (Jalife and Pandit, 2005; Cabo et al., 
1996) (Figure 1.6).  Such rotors are self-
sustaining and may be stationary or may drift 
but subsequently anchor themselves to 
anatomical structures in the atria. 
Further research has shown that there is a wide spectrum of spatial and temporal 
organisation of AF in the structurally normal heart (Skanes et al., 1998; Mandapati et 
al., 2000).  At one end of the spectrum, a single drifting rotor can give rise to complex 
patterns of activation that are reminiscent of AF.  At the other end, sustained AF may 
also depend on the periodic activity of stationary rotors, which activate the atria at very 
high frequencies (Chen et al., 2000).  These findings have been corroborated in humans 
by observations made during catheter ablation procedures for AF (Haissaguerre et al., 
2000b; Lu et al., 2001).  In addition, ectopic activity from the pulmonary veins that 
encounters heterogeneously refractory myocardium at the pulmonary vein-left atrial 
junction can result in the formation of rotors which generate high frequency impulses 
that propagate through the rest of the atria as fibrillatory waves (Mandapati et al., 2000; 
Jalife et al., 1998). 
Transmural rotors and the three-dimensional AF substrate 
Endo-epicardial dissociation of electrical activity and epicardial breakthrough during 
AF was first described by Schuessler et al. (1993) in a canine right atrial model.  They 
reported that the differences in epicardial and endocardial activation were related to the 
heterogeneous architecture of the right atrial wall and that reentry could occur in the 
three-dimensional plane via transmural muscle fibres (Schuessler et al., 1993).  More 
recently, Eckstein et al. (2011) performed simultaneous high-density endo-epicardial 
mapping on the left atrial free wall of goats during AF.   
Figure 1.6: Left Atrial Rotor 
LA, left atrium; RA, right atrium 
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They demonstrated that the degree of dyssynchrony between epicardial and endocardial 
activation increased from 17% after AF onset to 39% after 3 weeks, and 68% after 6 
months of continuous AF.  They postulated that this was due to progressive uncoupling 
between the epicardial and endocardial layers, which correlated with increasing stability 
and complexity of the AF substrate.  In a sheep model of persistent AF, Yamazaki et al. 
(2012) demonstrated that atrial scroll waves, defined as transmural rotors around a 
filament spanning the epicardial and endocardial surface, were the primary pattern of 
electrical activation.  Interestingly, the majority of atrial scroll waves were identified in 
thinner parts of the atrial wall or at the junction between thin and thick sections, which 
suggests that variability in atrial wall thickness is an important factor for AF 
persistence. 
1.7.3 Multiple Wavelet Reentry 
Over the past 50 years, multiple wavelet 
reentry has been the dominant conceptual 
model of AF (Figure 1.7).  It was proposed 
by Moe and Abildskov (1959) who 
reported that fractionation of wavefronts 
propagating through the atria resulted in 
self-perpetuating ‘daughter wavelets’.  The 
number of wavelets present at any one 
time depended on the refractory period, 
conduction velocity and mass in different 
parts of the atria; whereby, a large atrial 
mass with short, heterogeneous refractory 
periods and delayed conduction increased the number of wavelets, favouring 
maintenance of AF.  Experimental support for this hypothesis came from Allessie 
(1985) who estimated that four to six wavelets were needed to maintain AF in dogs.  
This theory was strengthened by the clinical observation that persistent AF could be 
cured in some patients by the creation of multiple surgical lesions (“Maze procedure”) 
to compartmentalise the atria into small areas that were unable to sustain the required 
number of wavelets (Cox et al., 1991). 
  
Figure 1.7: Multiple Wavelet Reentry (reproduced with 
permission from Konings et al. (1994)). ICV, inferior 
vena cava; LA, left atrium; PVs, pulmonary veins; RA, 
right atrium; SCV, superior vena cava 
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1.8 Autonomic nervous system 
The importance of the autonomic nervous system in initiating and maintaining atrial 
tachyarrhythmias was first described by Coumel in 1996.  Sympathetic stimulation 
increases ectopic activity via abnormal automaticity and afterdepolarisations; whereas, 
vagal stimulation shortens the atrial refractory period and increases its heterogeneity, 
which facilitates AF induction and maintenance via re-entrant mechanisms.  However, 
an imbalance between sympathetic and vagal stimulation rather than enhanced activity 
per se appears to be the critical factor 
particularly in paroxysmal (Tomita et 
al., 2003) but also persistent AF (Arora, 
2012).  AF onset is often preceded by 
increased sympathetic tone followed by 
predominantly parasympathetic activity 
(Amar et al., 2003).  The high density of 
adrenergic and cholinergic fibres in the 
posterior left atrium and pulmonary vein 
ostia likely contribute to the high 
frequency drivers and rotors primarily 
located at these sites (Yamazaki et al., 
2009; Ng et al., 2011) (Figure 1.8).  
Finally, Gould et al. (2006) demonstrated heightened atrial sympathetic innervation in 
patients with persistent AF and proposed that autonomic remodelling may play a role in 
the development of the AF substrate.   
1.9 AF-induced Remodelling 
The concept of tachycardia-induced remodelling was proposed by two independent 
experimental studies.  In a canine model of prolonged rapid atrial pacing, Morillo et al. 
(1995) found that the atrial refractory period was reduced by 15% and that after 6 
weeks, they could induce AF episodes > 15 minutes duration in 82% of the dogs.  In a 
goat model, Wijffels et al. (1995) maintained AF using epicardial burst pacing as soon 
as sinus rhythm returned.  This resulted in more pronounced shortening of atrial 
refractory periods (45% reduction) and a loss of their normal physiological rate 
adaptation.   
  
Figure 1.8: Major Left Atrial Ganglionic Plexi 
IVC, inferior vena cava; LIPV, left inferior pulmonary 
vein; LSPV, left superior pulmonary vein; RIPV, right 
inferior pulmonary vein; RSPV, right superior 
pulmonary vein; SVC, superior vena cava. 
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During the control 
period, only short 
paroxysms of AF were 
induced by burst pacing.  
After 2 days of AF, the 
paroxysms lasted longer 
than four hours and after 
2-3 weeks, 90% of the 
goats were in persistent 
AF (Figure 1.9).  This 
observation of 
tachycardia-induced remodelling led to the concept that ‘AF begets AF’ (Wijffels et al., 
1995).  AF-induced remodelling can be subdivided into three categories: (1) Electrical 
(2) Contractile and (3) Structural, with each contributing synergistically to the 
development of the AF substrate. 
1.9.1 Electrical Remodelling 
The increased susceptibility to AF is explained by shortening of the wavelength of the 
atrial reentrant circuit (Rensma et al., 1988).  When the wavelength is short, small areas 
of intra-atrial conduction block may serve as the origin of a re-entrant circuit, thus 
increasing the propensity for AF.  In addition, wavelength shortening allows more 
reentrant wavelets to coexist in the atria thus stabilising the arrhythmia.  The most 
important impact of AF on the ion channels in atrial cardiomyocytes is a marked 
reduction in the L-type Ca2+ current, which explains the shortening of the atrial action 
potential and the loss of its normal physiological rate adaptation (Yue et al., 1997; 
Bosch et al., 1999).  In addition, intracellular Ca2+ overload can cause delayed 
afterdepolarisations, which in turn can trigger ectopic activity and AF initiation.   
An important aspect of electrical remodelling is its reversibility.  Even after several 
years of continuous AF, atrial refractory periods can return to baseline with normal 
physiological rate adaptation within a few days of restoring sinus rhythm (Wijffels et 
al., 1995; Yu et al., 1999).  This has important clinical implications as recurrences of 
AF that occur after one week of sinus rhythm cannot be attributed to electrical 
remodelling. 
  
Figure 1.9: AF-induced Remodelling. Prolongation of AF episodes after 
electrically maintaining AF for 24 hours and 2 weeks in a goat model 
(reproduced with permission from Wijffels et al. (1995)). 
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Connexins 
Connexins are transmembrane ion channel proteins that are present in the gap junctions 
of cardiomyocytes and are responsible for transferring ions or molecules freely between 
cells, thereby coupling them electrically.  Cx40 and Cx43 are the two main connexins 
expressed in human atria (Saffitz et al., 1999).  Given the pivotal role that connexins 
play in cell-to-cell coupling, changes in their expression and distribution would be 
expected to have profound effects on cardiac conduction (Wakili et al., 2011).  
However, the results from a wide range of clinical and experimental studies show 
significant variations, with opposing results observed within the same model (Haugan et 
al., 2006; Ryu et al., 2007).  Pharmacological drugs that enhance gap junction 
conductance have been shown to be of benefit in some AF models (mitral valve disease 
and ischaemia) but not others (heart failure) (Guerra et al., 2006; Shiroshita-Takeshita et 
al., 2007).  Therefore, the role of connexin abnormalities and the therapeutic value of 
augmenting gap junction conductance in AF remain unclear. 
1.9.2 Contractile Remodelling 
Logan et al. (1965) documented that the A-wave in the atrial pressure curve was lost 
after electrical cardioversion of AF to sinus rhythm.  Subsequent echocardiographic 
research revealed that this atrial contractile dysfunction correlated with the duration of 
AF and could take months to fully recover (Manning et al., 1994 and 1995).  This 
delayed recovery of atrial contractility may play a role in the occurrence of 
thromboembolic events in the initial period following cardioversion (Black et al., 1994).  
Experimental and clinical studies have shown that verapamil (a calcium channel 
antagonist) was able to substantially reduce the degree of atrial contractile dysfunction 
after short periods of AF, indicating that “atrial stunning” in this population is mediated 
by Ca2+ overload (Leistad et al., 1996; Daoud et al., 1999).  Longer episodes of atrial 
fibrillation are associated with a 70% downregulation of the L-type Ca2+ current in a 
canine model (Yue et al., 1997).  This Ca2+ current is a major factor in determining both 
the calcium content and its release from the sarcoplasmic reticulum, which explains its 
role in AF-induced contractile dysfunction and remodelling. 
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1.9.3 Structural Remodelling  
The development of a fixed structural reentry 
substrate is a critical component in the 
progression of AF from paroxysmal to 
persistent and finally permanent forms (Figure 
1.10).  Atrial structural changes observed in 
animal models and in atrial biopsies from 
patients with AF include atrial dilatation and 
hypertrophy, dedifferentiation, fibrosis, 
apoptosis and myolysis (Ausma et al., 1997; 
Everett et al., 2000; Bauer et al., 2004; Anne et 
al., 2007). 
Atrial dilatation and hypertrophy 
Atrial dilatation has been frequently observed 
in animal models of AF (Everett et al., 2000; 
Bauer et al., 2004).  Schoonderwoerd et al. (2004) observed no atrial dilatation after 
rapid atrial pacing with a controlled ventricular rate for 4 weeks in a goat model, in 
contrast to the goats that were rapidly paced in both the atria and ventricles.  This 
suggests that a concurrent high ventricular rate resulting in haemodynamic 
decompensation is an important determinant of atrial dilatation.  Atrial cardiomyocyte 
hypertrophy has also been seen in pacing-induced animal models of AF (Ausma et al., 
1997; Anne et al., 2007).  Atrial dilatation and cardiomyocyte hypertrophy are 
commonly observed in patients with AF and are related to the severity of underlying 
cardiovascular disease and AF burden (Anne et al., 2005; Sanfilippo et al., 1990; 
Frustaci et al., 1997). 
Dedifferentiation 
Another adaptive mechanism contributing to structural remodelling involves a change 
in the gene expression profile to a more foetal phenotype – ‘dedifferentiation’.  Genes 
expressed during development are re-expressed, including skeletal α-actin, β-myosin 
heavy chain and atrial natriuretic peptide, and adult isoforms are downregulated (Ausma 
and Borgers, 2002).   
  
Figure 1.10: AF Progression. Focal ectopic 
drivers are principally associated with paroxysmal 
AF, functional reentry substrates with persistent AF 
and fixed structural reentry substrates with 
permanent AF. Reproduced with permission from 
Wakili et al. (2011). 
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Structural manifestations of dedifferentiation include myolysis, glycogen accumulation, 
mitochondrial changes, chromatic dispersion and loss of sarcoplasmic reticulum, which 
have been demonstrated in animal models (Ausma et al., 1997; Bauer et al., 2004; 
Schoonderwoerd et al., 2004) and in atrial biopsies from patients with AF (Rucker-
Martin et al., 2002).  It is thought that re-expression of a more foetal phenotype is an 
adaptive mechanism to meet the high energy demands associated with AF by allowing 
cardiomyocytes to use energy more efficiently (Barth et al., 2005). 
Fibrosis 
Fibrosis is the hallmark of structural remodelling (Li et al., 1999).  It is caused by an 
accumulation of collagen deposits, occurring most commonly as a reparative process to 
replace degenerating myocardial parenchyma in conjunction with reactive fibrosis, 
which causes interstitial expansion (Assayag et al., 1997; Silver et al., 1990).  Atrial 
fibrosis involves multifactorial processes that result from complex interactions between 
neurohormonal and cellular mediators.  In addition, there are extensive interactions 
between cardiomyocytes and fibroblasts (Burstein and Nattel, 2008).  Fibroblasts 
produce fibrotic extracellular matrix proteins and cardioactive mediators that affect the 
cardiomyocyte phenotype, whereas cardiomyocyte-derived products, such as 
angiotensin II, transforming growth factor β1, platelet-derived growth factor and 
connective tissue growth factor modulate fibroblast properties and synthesis of the 
extracellular matrix.  Reparative fibrosis replaces dead cardiomyocytes and therefore 
interferes with electrical continuity and slows conduction, whereas fibroblasts couple 
electrically to cardiomyocytes and promote ectopic activity and reentry (Burstein and 
Nattel, 2008; Yue et al., 2011). 
Apoptosis and Myolysis 
Apoptosis is defined as programmed cell death, whereas necrosis involves cell death 
that is caused by external factors (Hengartner, 2000).  Atrial biopsies from patients with 
AF have shown both apoptosis and necrosis (Frustaci et al., 1997; Aime-Sempe et al., 
1999).  As previously described with atrial dilatation (Schoonderwoerd et al., 2004), 
there was no evidence of atrial cell death in a goat model with rapid atrial pacing and a 
controlled ventricular rate.  However, atrial cell death was observed in two animal 
models that received combined rapid atrial and ventricular pacing (Schoonderwoerd et 
al., 2004; Li et al., 1999), which highlights the importance of a high ventricular rate and 
subsequent haemodynamic deterioration in structural remodelling.   
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Myolysis is defined as loss of cellular myofibril structure and is more consistently seen 
in models of persistent AF and cardiac failure than in patients with paroxysmal AF and 
structurally normal hearts (Frustaci et al., 1997).   
1.9.4 Atrial Stretch 
Studies using animal models of atrial volume (Nazir and Lab, 1996) and pressure (Bode 
et al., 2000) overload have shown an association between atrial stretch and an increased 
vulnerability to atrial arrhythmias.  Interestingly, no spontaneous AF occurred in these 
animals suggesting the presence of an AF substrate without initiating triggers.  In 
humans, hypertension, mitral valve disease and other models of left atrial overload are 
associated with atrial stretch and dilatation and an increased vulnerability to AF (Lau et 
al., 2010; Verheule et al., 2003).  Atrial stretch facilitates the development of AF by 
causing both structural and electrical remodelling (Saygili et al., 2007; De Jong et al., 
2011). 
1.9.5 Inflammation and Oxidative Stress 
Inflammation has been linked to AF with inflammatory infiltrates seen in atrial biopsies 
from patients with lone AF (Frustaci et al., 1997).  Furthermore, serum levels of 
inflammatory markers are increased in both lone AF, as well as in AF associated with 
other comorbidities (Li et al., 2010).  Myeloperoxidase (MPO), a neutrophil component 
that is part of the inflammatory response, has been found in the atria of patients with 
AF.  An MPO infusion in MPO-deficient mice induced fibrosis and increased AF 
vulnerability, suggesting that MPO is a major protagonist in the development of atrial 
fibrosis (Rudolph et al., 2010).  Oxidative stress in the form of oxygen and nitrogen free 
radicals also plays a role in the development of AF by promoting structural remodelling 
in the form of atrial fibrosis and cardiomyocyte hypertrophy (Mihm et al., 2001; Reil et 
al., 2010). 
1.10 Management 
Management of AF is primarily aimed at reducing morbidity and mortality and 
improving quality of life.  More specific goals are ventricular rate control, restoration of 
sinus rhythm and prophylaxis against thromboembolism (Fuster et al., 2011).  For the 
purpose of this thesis, I will focus on rate vs. rhythm control and specifically catheter 
ablation as a therapeutic intervention for patients with AF.   
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1.10.1 Rhythm vs. Rate Control 
The fundamental decision of whether to choose rate-control vs. rhythm control as a 
treatment strategy in patients with AF has been the source of much debate amongst 
cardiologists (Cohen and Naccarelli, 2008).  Theoretically, the restoration and 
maintenance of sinus rhythm should be favourable compared to a rate-control strategy 
due to the normalisation of heart rate and restoration of chronotropic competence, atrial 
contractile function and atrioventricular synchrony.  Maintenance of sinus rhythm is 
associated with reduced atrial remodelling and AF symptoms, improved left ventricular 
function and exercise tolerance, and improved quality of life.  However, prior to the 
development of AF ablation, the theoretical benefit of rhythm control relied on the 
availability of safe, tolerable and effective antiarrhythmic drugs.  Comparative studies 
such as Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) 
(Wyse et al., 2002), Pharmacological Intervention in Atrial Fibrillation [PIAF] 
(Hohnloser et al., 2000) and Atrial Fibrillation and Congestive Heart Failure (AF-CHF) 
(Roy et al., 2008) have shown suboptimal rates of restoration and maintenance of sinus 
rhythm with no survival benefit over rate-control therapy (Steinberg et al., 2004).  This 
is likely because the antiarrhythmic drugs studied had limited efficacy, poor tolerability 
and the potential for ventricular pro-arrhythmia.   
Figure 1.11: Choice of Antiarrhythmic Drug according to Comorbidity. ACEI = 
angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; CAD = 
coronary artery disease; CHF = congestive heart failure; HT = hypertension; LVH = left 
ventricular hypertrophy; NYHA = New York Heart Association; Antiarrhythmic drugs are 
listed in alphabetical order within each treatment box. Reproduced from Camm et al. (2010).  
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More importantly, there was a significantly higher incidence of non-cardiovascular 
deaths in the rhythm-control group (12%) versus the rate-control group (8%), which 
were attributed to pulmonary and cancer-related deaths (Wyse et al., 2002).  These 
results have strongly influenced current treatment guidelines to recommend rhythm-
control therapy only in AF patients with disabling symptoms (Fuster et al., 2011).  
When a rhythm-control strategy is chosen, the choice of antiarrhythmic drug is based on 
the patients’ comorbidities including hypertension, coronary artery disease and heart 
failure (Figure 1.11).  Regardless of whether restoration of sinus rhythm will be 
attempted, treatment of AF should always include control of the ventricular rate (Camm 
et al., 2010).  Pharmacological agents for rate control (β-blockers, non-dihydropyridine 
calcium channel antagonists, digoxin) either alone or in combination should be tailored 
to the individual patient based on underlying comorbidity and side effects such as 
bradycardia and hypotension.  A rate-control strategy may be appropriate for elderly 
patients with minimal AF symptoms and in patients who are likely to have significant 
structural remodelling already present on account of underlying disease where a 
rhythm-control strategy is unlikely to be successful (Cosio et al., 2008). 
1.11 Catheter Ablation 
The disappointing performance of antiarrhythmic drugs coupled with the consistently 
high success and low complication rates routinely achievable using catheter ablation for 
other cardiac arrhythmias led to the development of catheter-based ablation strategies 
for AF.  The initial procedures were designed to reproduce the success of the Cox Maze 
III surgical procedure using a transvenous catheter-based approach.  The Cox Maze III 
procedure (Cox et al., 1995) was based on the “multiple wavelet reentry” model of AF 
(Moe and Abildskov, 1959) and the concurrent observation that 4 to 6 wavelets were 
required to maintain AF in a canine model (Allessie, 1985).  It involved creating 
surgical incisions to divide the atria into small compartments to abort or block all 
possible anatomical reentrant circuits so that AF could not be initiated or maintained 
(Figure 1.12).  The Cox Maze III procedure eliminated AF in 97% of patients among 
whom 76% maintained sinus rhythm off antiarrhythmic drugs at 5-year follow up 
(Prasad et al., 2003).  However, the need for cardiopulmonary bypass along with its 
inherent risks and prolonged recovery time restricted its use to patients requiring 
additional cardiac surgery.   
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Unfortunately, attempts to replicate 
the Cox Maze III procedure using 
intracardiac catheters have had limited 
success despite the use of three-
dimensional electroanatomical 
mapping systems and multipolar 
ablation catheters (Haissaguerre et al., 
1996; Pappone et al., 1999). 
1.11.1 Pulmonary Vein Ablation 
The landmark observation by 
Haissaguerre and colleagues that AF 
was often triggered by ectopic foci 
within the pulmonary veins 
(Haissaguerre et al., 1994; Jais et al., 
1997; Haissaguerre et al., 1998) led to 
a monumental shift in the direction of 
AF ablation towards abolishing these 
focal triggers.  Catheter ablation of 
these ectopic foci was hampered by the 
difficulty in precisely mapping their 
location within the three-dimensional 
pulmonary venous structure and therefore, Haissaguerre and colleagues developed a 
segmental ablation technique that was designed to electrically isolate the myocardial 
sleeves of the pulmonary veins at their ostium (Haissaguerre et al., 2000a).  The 
subsequent discovery that delivery of radiofrequency energy within the pulmonary 
veins could cause pulmonary vein stenosis (Robbins et al., 1998), coupled with the 
identification of focal triggers in the body of the left atrium led to the development of 
more extensive ablation strategies incorporating both the pulmonary veins and the atrial 
tissue surrounding the pulmonary veins – ‘pulmonary vein antrum’.  Ablation at these 
sites was either performed segmentally guided by a circular mapping catheter close to 
the pulmonary vein ostium (Haissaguerre et al., 2000a; Oral et al., 2002) or by wide 
area circumferential ablation (WACA) which involves the creation of wider continuous 
circumferential ablation lesions around the right and left pulmonary veins guided by 
three-dimensional electroanatomical mapping systems (Pappone et al., 1999 and 2000), 
fluoroscopy or intracardiac echocardiography (Callans et al., 2004).   
Figure 1.12: Original cut-and-sew Cox Maze 
procedure III. RA (right atrium): Excision of right 
atrial appendage, free wall incision, linear incision 
from superior vena cava to inferior vena cava (IVC) 
and from IVC to tricuspid valve annulus. LA (left 
atrium): Excision of left atrial appendage, pulmonary 
vein encirclement with extension to mitral valve 
annulus, and atrial septal incision. Reproduced from 
Weimar et al. (2012).   
RA 
LA 
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WACA targets arrhythmogenic foci within the pulmonary veins as well as high-
frequency sources and sites of local reentry in the pulmonary vein-left atrial junction 
and posterior left atrium, 
which are not included in 
segmental pulmonary vein 
ablation (Figure 1.13).  It 
can also result in atrial 
debulking as 25-30% of left 
atrial tissue can be 
electrically isolated from 
the remaining left atrium.  
In line with the above, 
WACA was found to be 
more effective that 
segmental pulmonary vein 
ablation in patients with 
paroxysmal AF in a 
randomised study (Oral et 
al., 2003).  The same group 
showed that WACA is also 
effective in patients with 
persistent AF with 74% of 
patients maintaining sinus rhythm off antiarrhythmic drugs at 1 year follow up (Oral et 
al., 2006b). 
1.11.2 Efficacy of Catheter Ablation 
Pulmonary vein isolation (PVI) alone is reported to achieve durable sinus rhythm 
without the need for antiarrhythmic drugs in 59-93% of patients (Oral et al., 2003; Van 
Belle et al., 2008; Fiala et al., 2008; Dixit et al., 2008; Arentz et al., 2003).  In addition, 
meta-analyses of studies (including mostly patients with paroxysmal AF) comparing 
antiarrhythmic drugs with catheter ablation, have shown a significantly higher 
proportion of patients maintain sinus rhythm after catheter ablation (Wilber et al., 2010; 
Calkins et al., 2009; Noheria et al., 2008; Jais et al., 2008; Wazni et al., 2005; Pappone 
et al., 2006).  These results have led to catheter ablation being recommended in patients 
with symptomatic paroxysmal AF that is resistant to at least one antiarrhythmic drug 
(Camm et al., 2010).   
Figure 1.13: Electroanatomical map showing wide area 
circumferential ablation (WACA). Ablation lines circumscribe 
and divide the left and right pulmonary veins. A “Roof line” 
connecting the left and right superior pulmonary veins and “Mitral 
line” connecting the left inferior pulmonary vein to the mitral 
valve annulus are also shown. LA – left atrium, LIPV – left 
inferior pulmonary vein, LSPV – left superior pulmonary vein, 
MVA – mitral valve annulus, RIPV – right inferior pulmonary 
vein, RSPV – right superior pulmonary vein. Reproduced from 
Packer (2004). 
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It can also be considered as a first-line management strategy in patients with 
symptomatic paroxysmal AF and no/minimal structural heart disease (Camm et al., 
2010).  Unfortunately, the acute and longer-term success rates of catheter ablation for 
patients with persistent AF remain significantly lower than for patients with paroxysmal 
AF despite the development of additional ablation strategies aimed at positively 
modifying the AF substrate.  These additional ablation strategies include linear left 
atrial, complex fractionated atrial electrogram (CFAE) and ganglionic plexus ablation 
(autonomic denervation).  In a systematic review and meta-analysis of long-term 
outcomes (≥ 3 years) of catheter ablation in 6167 patients with AF, Ganesan et al. 
(2013) reported an overall single procedure success rate of 53.1% (54.1% paroxysmal; 
41.8% persistent, p=0.3), which increased to 79.8% (79% paroxysmal; 77.8% 
persistent, p=0.9) after multiple procedures (mean 1.51 procedures per patient – 1.45 
paroxysmal vs. 1.67 persistent AF, p=0.2).  The authors noted that there was significant 
heterogeneity in the procedure outcome data and also did not include any patients with 
longstanding persistent AF in the meta-analysis due to the small number of patients 
with long-term follow up.  A systematic review of catheter ablation outcomes in 
patients with longstanding persistent AF concluded that, with the exception of PVI 
alone (21% success) and CFAE ablation alone (37% success), all substrate ablation 
techniques including WACA alone or in combination with linear left atrial or CFAE 
ablation provided comparable clinical outcomes (mean success 47%) (Brooks et al., 
2010).  In light of the lower success rates observed with persistent and longstanding 
persistent AF, there is currently much debate amongst electrophysiologists regarding the 
optimum ablation strategy for these patients. 
1.11.3 Linear Left Atrial Ablation 
Linear ablation was conceived with the aim of reproducing the success of the Cox Maze 
III surgical ablation procedure (Cox et al., 1995) by compartmentalising the left atrium, 
thereby preventing the formation of macroreentrant circuits that can maintain AF.  It 
involves the creation of linear ablation lesions that connect electrically inert structures 
with the commonest being the “Roof line” (connecting the right upper and left upper 
pulmonary veins), “Mitral line” (connecting the left lower pulmonary vein to the mitral 
valve annulus) and “Inferior line” (connecting the right lower pulmonary vein to the 
roof of the coronary sinus).  Ablation strategies using a stepwise combination of PVI, 
CFAE and linear left atrial ablation achieved higher success rates compared to PVI 
alone in patients with persistent AF (42-95% freedom from AF without antiarrhythmic 
drugs) with most centres reporting success rates >70% (Haissaguerre et al., 2005; 
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Willems et al., 2006; Fassini et al., 2005; O'Neill et al., 2009; Estner et al., 2008a).  
However, two or more ablation procedures were required in ~50% patients to control 
persistent AF.  In addition, incomplete bidirectional block across linear ablation lesions 
can be responsible for the occurrence of macroreentrant left atrial flutter post procedure, 
which can be incessant and frequently associated with significant symptoms (Matsuo et 
al., 2010; Ouyang et al., 2002; Tzeis et al., 2010). 
1.11.4 Complex Fractionated Atrial Electrogram (CFAE) Ablation 
This approach was first described by Nademanee et al. (2004) and involves targeting 
areas of myocardium that demonstrate CFAEs.  CFAEs are defined as: (1) atrial 
electrograms that have two or more deflections from the baseline and/or perturbation of 
the baseline with continuous deflection of a prolonged activation complex over a 10-
second recording period (Figure 1.14); (2) atrial electrograms with a cycle length 
≤120ms averaged over a 10-second recording period.  Konings et al. (1997) reported 
that CFAEs observed during 
intraoperative mapping of AF were 
mostly found in areas of slow 
conduction and/or at pivot 
points where reentrant wavelets 
enter areas of functional block.  
Therefore, it has been 
hypothesised that CFAEs 
represent areas of the atrial 
substrate that are critical to 
the perpetuation of AF 
(Nademanee et al., 2004; 
Konings et al., 1997; Jais 
et al., 1996).   
The aforementioned study by Nademanee et al. (2004) targeted and eliminated CFAEs 
in 121 patients with AF (64 persistent).  At the end of procedure, all of the patients with 
paroxysmal AF and 58 (91%) patients with persistent AF were in sinus rhythm.  At 1 
year follow up, 110 (91%) patients were free from symptomatic AF.  However, other 
groups have not been able to replicate these impressive results, which has cast doubt on 
the value of CFAE ablation.   
  
Figure 1.14: CFAEs in the posterior septum. Reproduced from 
Nademanee et al. (2004). 
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Estner et al. (2008b) reported that only 2/23 (9%) patients with persistent AF who 
underwent CFAE ablation alone were in sinus rhythm without the need for 
antiarrhythmic drugs after a single procedure, compared with 22/54 (41%) patients who 
received CFAE ablation and PVI.  Oral et al. (2009) reported the effect of CFAE 
ablation in conjunction with PVI in 119 patients with persistent AF.  AF terminated 
during PVI in only 16% of patients and no difference in outcome was observed among 
the remaining patients who were randomised to either CFAE ablation or electrical 
cardioversion.  The subjective nature of defining CFAEs by visual inspection alone 
could explain why other groups have been unable to replicate the success of Nadamanee 
and colleagues.  In light of this, software algorithms to automatically identify CFAE 
sites have been developed (Calo et al., 2008).  The other possible explanation is that 
CFAEs simply represent areas of wavelet collision, which are not critical to the 
maintenance of AF. 
1.11.5 Autonomic Ganglion Plexus Ablation 
The intrinsic cardiac autonomic nervous system contains plexi of autonomic ganglia 
located in epicardial fat pads and the ligament of Marshall (Armour et al., 1997).  
Ganglionic plexi (GP) contain afferent neurons from the atrial myocardium and central 
autonomic nervous system and efferent cholinergic and adrenergic neurons, which 
innervate the adjacent pulmonary vein and atrial myocardium.  For endocardial GP 
ablation, a vagal response to high frequency stimulation is used to identify GPs, which 
are targeted with radiofrequency energy.  A meta-analysis of 1147 patients who 
underwent catheter ablation demonstrated that PVI + cardiac autonomic denervation 
(CAD) significantly reduced the recurrence rate of atrial arrhythmias in both 
paroxysmal (OR 1.69; 95% CI: 1.09-2.62) and persistent (OR 2.11; 95% CI: 1.14-3.90) 
AF groups (Zhang et al., 2012).  The authors also compared CAD to PVI and found no 
difference in ablation outcome (OR 0.31; 95% CI: 0.11-0.86). 
1.11.6 Focal Impulse and Rotor Modulation (FIRM) Ablation 
Narayan et al. (2012) have recently developed a novel computational mapping approach 
to detect rotors and focal impulses from atrial electrograms recorded during AF using 
the Constellation™ full-contact 64-pole basket catheter (Boston Scientific) (Figure 
1.15).  In a cohort of 92 patients (107 consecutive ablation procedures) with AF (72% 
persistent), they observed localised rotors or focal impulses in 98 (97%) cases with 
sustained AF, with a mean of 2.1 ± 1.0 sources per patient.   
  
 21 
 Patients were prospectively allocated to FIRM followed by conventional ablation (PVI 
using WACA in all patients and additional left atrial roof line in patients with persistent 
AF) (n=36) or conventional ablation alone (n=71).  The acute endpoint (AF termination 
or ≥10% increase in AF cycle length) was achieved in 86% of FIRM + conventional 
ablation group vs. 20% conventional ablation group (p<0.001).  After a single 
procedure, 82.4% patients in the FIRM group were free from AF vs. 44.9% in the 
conventional ablation group (p<0.001) at a median follow-up of 273 days (Narayan et 
al., 2012).  FIRM ablation is the most exciting development in AF ablation in recent 
years although it remains to be seen whether these impressive results can be replicated 
in large multicentre randomised controlled trials comparing FIRM vs. conventional 
ablation strategies. 
1.11.7 Ablation Technologies 
Radiofrequency Energy 
The theoretical basis of successful AF ablation is the production of transmural 
myocardial lesions that electrically isolate rapidly firing ectopic foci coupled with 
modification of the arrhythmogenic atrial substrate that facilitates reentry.  
Radiofrequency energy achieves myocardial ablation by the conduction of alternating 
electrical current through myocardial tissue, which exhibits electrical resistance.  This 
tissue resistance results in the dissipation of RF energy as heat resulting in irreversible 
coagulation necrosis and ultimately the formation of non-conducting myocardial scar 
(Haines, 2006).  High power delivery and good electrode-tissue contact using large-tip 
or irrigated-tip catheters promote the formation of larger ablation lesions and improve 
procedural efficacy.   
  
Figure 1.15: Acute termination of AF to sinus rhythm by FIRM Ablation. (A) Right atrial clockwise 
rotor and simultaneous left atrial focal impulse in a patient with persistent AF. (B) FIRM ablation at the 
site of the right atrial rotor terminated AF in 5.5 minutes. CS = coronary sinus electrogram. Reproduced 
from Narayan et al. (2012). 
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Comparative trials of open-loop irrigated-tip and standard 4mm-tip catheters have 
demonstrated an improvement in the maintenance of sinus rhythm after ablation with 
open-loop irrigated-tip catheters in conjunction with a similar complication rate 
(Thomas et al., 2004; Chang et al., 2009). 
Multielectrode circumferential ablation catheters 
The principal purpose of multielectrode 
circumferential ablation catheters is to provide 
mapping and ablation in a single platform.  One 
example is the PVAC® catheter (Medtronic 
Ablation Frontiers) which is a circular, decapolar 
catheter that creates ablation lesions by delivering 
radiofrequency energy at a relatively low power 
(Figure 1.16).  In a prospective cohort study of 
110 patients with symptomatic paroxysmal AF, 57 
(52%) patients were arrhythmia free off 
antiarrhythmic drugs at 1-year follow up (Mulder 
et al., 2011).  This compares favourably to the radiofrequency and cryoballoon-based 
AF ablation literature (Andrade et al., 2011 and 2012; Ganesan et al., 2013). 
Cryoablation 
Within the last decade, cryoablation has superseded 
the original “cut and sew” technique for performing 
the Cox Maze procedure for the surgical treatment 
of AF on account of its similar efficacy and 
significantly reduced cardiopulmonary bypass time.  
In a non-randomised trial of patients with AF 
requiring mitral valve surgery, Nakajima et al. 
(2002) compared the efficacy of cryoablation 
versus the original “cut and sew” technique in 
performing the Cox Maze procedure and reported 
no significant difference in the number of patients 
in sinus rhythm at discharge: 85% cryoablation vs. 86% ‘cut and sew’.  The Arctic 
Front® cryoballoon ablation system (Medtronic Cryocath) (Figure 1.17) was developed 
as a method of performing pulmonary vein isolation.  Liquid nitrous oxide is delivered 
under pressure to the cryoablation balloon, where it changes into gas, resulting in 
cooling of the surrounding tissue to temperatures below -40°C.   
Figure 1.16: PVAC® catheter in the ostium 
of the left lower pulmonary vein. A 
decapolar catheter in the coronary sinus is 
also shown. 
Figure 1.17: Arctic Front® cryoablation 
balloon and Achieve™ circular mapping 
catheter (Medtronic Cryocath) 
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Tissue freezing, with the creation of intracellular ice crystals, and rewarming results in 
cell death by disrupting cell membranes and interrupting cellular metabolism and 
intracellular electrical activity.  As with radiofrequency energy, good tissue contact is 
required to generate effective ablation lesions.  Blood flow around the cryoablation 
balloon counteracts the effects of cooling, thus reducing the likelihood of a transmural 
ablation lesion.  Therefore, complete vein occlusion is required to create circumferential 
pulmonary vein lesions and durable PVI.   
There are several potential advantages with using cryoablation.  Balloon adhesion to 
myocardial tissue during freezing enhances the efficacy of ablation lesions and allows 
the operator to pivot the balloon on the adhered section to reach other areas of the 
pulmonary vein ostium which is particular useful when treating large diameter 
pulmonary veins.  Cryoablation also carries a low risk of thrombus formation (Khairy et 
al., 2003), which potentially reduces the risk of thromboembolic complications.   
In a systematic review of the efficacy and safety of cryoballoon ablation in 1298 
patients (1211 paroxysmal AF), Andrade et al. (2011) reported that pulmonary vein 
isolation was achieved in 98.8% of patients.  One-year freedom from recurrent AF was 
72% in patients with paroxysmal and 45% in patients with persistent AF.  Three non-
randomised studies comparing cryoballoon versus radiofrequency ablation reported no 
difference in arrhythmia outcomes (Linhart et al., 2009; Kojodjojo et al., 2010; Kuhne 
et al., 2010).   
1.11.8 Safety 
In a worldwide survey on the safety of catheter ablation for AF, Cappato et al. (2010) 
reported an overall complication rate of 4.5% including vascular complications (1.47%), 
cardiac tamponade (1.31%), stroke / transient ischaemic attack (0.94%), pulmonary vein 
stenosis requiring intervention (0.29%) and death (0.15%).  It should be highlighted that 
this data was taken from voluntary surveys and therefore likely underestimates the true 
complication rates.  A systematic review of the safety and efficacy of AF ablation using 
phased radiofrequency energy and multielectrode catheters reported an acute procedural 
complication rate (stroke, myocardial infarction, pericardial effusion or tamponade, and 
vascular access complications) of 2% in 1719 patients from 25 studies (Andrade et al., 
2012).  However, two separate studies (Herrera Siklody et al., 2011; Gaita et al., 2011) 
reported a significantly higher rate of silent cerebral ischaemic lesions after PVAC® 
ablation (37.5 – 45.1%) when compared to irrigated radiofrequency (7.4 – 16.7%) and 
cryoballoon ablation (4.3 – 5.6%).  Importantly, Schwarz et al. (2010) demonstrated that 
these lesions might be associated with neuropsychological sequelae.   
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Haines et al. (2013) investigated this further using a porcine model and demonstrated 
that left atrial ablation using irrigated tip radiofrequency and PVAC® catheters was 
associated with microbubble and microembolus production.  They hypothesised that 
this could explain the ischaemic cerebral lesions seen on diffusion weighted MRI and 
reported that bipolar ablation using electrodes 1 and 10 on the PVAC® catheter was 
associated with the most microbubbles due to electrode overlap.  These findings were 
corroborated by Wieczorek et al. (2013) in a study of 37 patients with paroxysmal AF 
and this has been addressed in the design of the new PVAC® Gold catheter (Medtronic 
Ablation Frontiers) which has nine electrodes and therefore eliminates the potential 
overlap between electrodes 1 and 10. 
Regarding the safety of cryoballoon ablation, Andrade et al. (2011) reported that the 
commonest complication was phrenic nerve paralysis with an incidence of 4.7%.  This 
was transient in the majority of cases with only 0.37% experiencing phrenic nerve 
paralysis 1 year following ablation.  Other complications were less frequent including 
vascular complications (1.8%), cardiac tamponade / pericardial effusion (1.5%), 
thromboembolic complications (0.6%), and significant pulmonary vein stenosis (0.2%). 
1.11.9 Effect on Stroke Risk and Mortality 
Our knowledge of the long-term effects of catheter ablation on mortality and risk of 
stroke has increased significantly over the past decade.  In a retrospective analysis of 
775 patients who underwent AF ablation with 2-year follow up, Oral et al. (2006a) 
demonstrated that patients who maintained sinus rhythm after ablation had the same risk 
of stroke as patients in the control group from the Framingham study with no history of 
AF.  In an epidemiological study of 4212 patients who underwent AF ablation 
compared to age and gender-matched controls with and without AF, patients in the AF 
ablation group had a significantly lower risk of death and stroke in comparison to AF 
patients who did not receive ablation during a 3-year follow up period (Bunch et al., 
2011).  Interestingly, the reduction in stroke risk and mortality was not exclusively 
dependent on maintaining sinus rhythm after ablation in this study.  These findings have 
been corroborated by Lin et al. (2013) who compared long-term outcome and mortality 
in 384 AF patients with high thromboembolic risk (CHA2DS2-VASC score ≥1) – 174 
patients who underwent AF ablation and 174 propensity-matched patients who received 
antiarrhythmic medication.  At 4-year follow up, 90.2% patients maintained sinus 
rhythm in the ablation group vs. 39.7% patients in the medically treated group 
(p<0.001).   
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Mortality and stroke rates were significantly lower in the ablation group compared to 
the medically treated group (2.9% and 2.3% vs. 11.5% and 8.6% respectively).  In 
addition, patients who maintained sinus rhythm after ablation had significantly lower 
mortality and stroke rates than patients who experienced recurrent AF (1.7% and 0.8% 
vs. 5.4% and 5.4% respectively).  Furthermore, AF recurrence also predicted the future 
occurrence of a major adverse cardiovascular or vascular event in a multivariate Cox 
regression analysis of the ablation group.  In summary, there is a growing body of 
evidence that catheter ablation reduces stroke risk and mortality in patients with AF; 
although, more definitive results are expected from the ongoing prospective CABANA 
(Catheter ABlation vs. ANtiarrhythmic drug therapy for Atrial fibrillation) and EAST 
(Early treatment of Atrial fibrillation for Stroke prevention Trial) randomised controlled 
studies. 
 
I would now like to present the remaining six chapters of my thesis, which focus on the 
three main studies I completed during my MD research programme.  The unifying aim 
of the thesis was to investigate whether we could predict and improve clinical outcome 
following ablation in patients with AF using surface AF waveform analysis and 
multipolar contact mapping respectively.  Each chapter is presented in manuscript 
format with an individual Abstract, Introduction (including specific Aims), Methods, 
Results and Discussion.  In brief, Chapter 2 examines whether the inclusion of posterior 
ECG leads improves correlation between surface dominant AF frequency (calculated 
using principal component analysis) and intracardiac measurements from the left 
atrium.  Chapter 3 explores whether acute and 12-month outcome following catheter 
ablation can be predicted beforehand using clinical and surface AF waveform 
parameters.  Chapter 4 considers the effect of catheter ablation on AF symptoms and 
quality of life.  Chapters 5 and 6 examine the role of multipolar contact mapping in 
facilitating catheter ablation in patients with persistent AF.  Chapter 7 concludes with a 
final discussion of the main results of the studies including their clinical relevance and 
directions for future research.  
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Chapter 2.  Principal component analysis of atrial fibrillation: 
Inclusion of posterior ECG leads does not improve correlation with left 
atrial activity 
2.1 Abstract 
Background 
Lead V1 is routinely analysed due to its large amplitude AF waveform.  V1 correlates 
strongly with right atrial activity but only moderately with left atrial activity.  Posterior 
lead V9 correlates strongest with left atrial activity. 
Aims 
[1] To establish whether surface dominant AF frequency (DAF) calculated using 
principal component analysis (PCA) of a modified 12-lead ECG (including posterior 
leads) has a stronger correlation with left atrial activity compared to the standard ECG; 
[2] To assess the contribution of individual ECG leads to the AF principal component in 
both ECG configurations. 
Methods 
Patients were assigned to modified or standard ECG groups.  In the modified ECG, 
posterior leads V8 and V9 replaced V4 and V6.  AF waveform was extracted from one-
minute surface ECG recordings using PCA.  Surface DAF was correlated with 
intracardiac DAF from the high right atrium (HRA), coronary sinus (CS) and 
pulmonary veins (PVs). 
Results 
96 patients were studied.  Surface DAF from the modified ECG did not correlate better 
with left atrial activity compared to the standard ECG.  Both ECG configurations 
correlated strongly with HRA, CS and right PVs (p<0.01) but only moderately with left 
PVs (p<0.05).  V1 contributed most to the AF principal component in both ECG 
configurations. 
Conclusion 
Surface DAF calculated using PCA of a modified 12-lead ECG (including posterior 
leads) did not correlate better with left atrial activity compared to the standard ECG.  
Surface DAF from both ECG configurations correlated strongly with right atrial 
activity, reflecting the dominance of lead V1 in the AF principal component. 
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2.2 Introduction 
It is widely accepted that the atrial waveform seen on the surface ECG during AF 
reflects intracardiac electrical activity (Alcaraz et al., 2011; Petrutiu et al., 2009).  The 
majority of research studies investigating surface ECG analysis in AF employ QRST 
subtraction as the method of extracting the AF waveform from the surface ECG.  The 
two principal methods of QRST subtraction are average beat subtraction (ABS) and 
spatiotemporal QRST cancellation.  ABS was initially developed to help identify P 
waves in ventricular tachycardia (Slocum et al., 1985) and involves creation of an 
average QRST complex from a single ECG lead, which is then subtracted to leave the 
residual atrial signal (Bollmann et al., 1998; Holm et al., 1998).  It relies heavily on the 
assumption that the average QRST complex reflects each individual QRST complex 
accurately.  However, QRST morphology can vary with the orientation of the heart’s 
electrical axis and therefore, minor axis variations can result in significant QRST 
residuals appearing in the extracted AF waveform.  Spatiotemporal QRST cancellation 
was developed to address this problem by using a multi-lead ECG (typically leads II, 
aVF and V1) to compensate for variations in electrical axis by transferring information 
between leads (Stridh and Sornmo, 2001).  The majority of studies analysing the body 
surface AF waveform using these techniques have focused on lead V1 due to the 
relatively large amplitude AF waveform in this lead.  This reliance on lead V1 detracts 
from the sensitivity of the results since V1 has been shown to correlate strongly with 
right atrial activity (r=0.89) but only moderately with left atrial activity (r=0.62) 
(Petrutiu et al., 2009).  In the same study, posterior lead V9 had the strongest correlation 
with left atrial activity (r=0.88) (Petrutiu et al., 2009).  Therefore, results obtained using 
QRST subtraction of V1 will have an inherent right atrial bias and may not accurately 
reflect left atrial activity. 
As an alternative to template subtraction methods, blind source separation techniques 
have been applied to extract atrial components from multi-lead recordings of AF by 
suppressing ventricular complexes (Langley et al., 2006; Raine et al., 2004; Rieta et al., 
2004).  The main advantage of these techniques is that they derive a ‘global’ AF 
waveform that has contributions from all ECG leads.  One such method uses principal 
component analysis (PCA) (Langley et al., 2006; Raine et al., 2004).  Using a 
combination of PCA and Fourier analysis, we have previously shown that surface DAF 
is reproducible over time and changes appropriately with drug manipulation of the 
arrhythmia (Raine et al., 2004).
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We have also demonstrated a reduction in surface DAF following creation of linear 
ablation lesions in the left atrium (Raine et al., 2005).  So far the focus of this work has 
been on the standard 12-lead ECG.  However, given the evidence that posterior leads 
may provide a more accurate reflection of left atrial activity (the chamber responsible 
for the initiation and maintenance of AF in the majority of patients), the aims of this 
study were: [1] To establish whether surface DAF calculated using PCA of a modified 
12-lead ECG (including posterior leads V8 and V9) had a stronger correlation with left 
atrial activity compared to the standard 12-lead ECG; [2] To assess the contribution of 
individual ECG leads to the AF principal component in both ECG configurations. 
2.3 Materials 
2.3.1 Patient Recruitment and Clinical Characteristics 
Study participants were recruited from patients with AF undergoing their first catheter 
ablation procedure for standard clinical indications.  Class I and III antiarrhythmic drugs 
were discontinued five half-lives prior to ablation.  Patients were excluded from the 
study if they were unable to give written informed consent or were taking amiodarone – 
because of its long half-life and effects on cardiac electrophysiology.  The clinical 
characteristics of the 96 consecutive patients studied are shown in Table 2.1.  Their 
mean age was 57 ± 10 years and 79% were male.  54% had persistent AF and the mean 
AF history was 4 ± 4 years. 
2.3.2 Ethical Approval 
This study complies with the Declaration of Helsinki and was granted a favourable 
ethical opinion by the National Research Ethics North West Committee (REC reference: 
11/NW/0476).  Written informed consent was obtained from all patients included in the 
study. 
2.3.3 Study Protocol 
Surface ECG and intracardiac recordings were collected simultaneously on a Labsystem 
Pro™ recording system (Bard EP) at a digital sampling rate of 1000Hz for offline 
analysis in Matlab®2013.  A one-minute recording was collected from patients in AF at 
the start of the procedure.  For patients in sinus rhythm, AF induction was attempted 
using routine pacing manoeuvres.  If AF was successfully induced, a 5-minute 
recording was collected to allow the arrhythmia to stabilise and AF parameters from the 
fifth minute were analysed.  Patients were excluded from the study if AF could not be 
initiated or did not sustain for at least 5 minutes. 
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Intracardiac recordings were collected from the coronary sinus (CS), high right atrium 
(HRA) and sequentially from each of the pulmonary vein ostia using a decapolar 
(Livewire™, St. Jude Medical), quadripolar (Josephson, St. Jude Medical) and bipolar 
irrigated-tip ablation catheter respectively.  The distal poles of the CS catheter were 
positioned on the lateral aspect of the mitral valve ring, with proximal bipole CS9-10 just 
inside the ostium of the coronary sinus.  The HRA catheter was positioned either in the 
right atrial appendage or high lateral right atrium depending on whether we were able to 
achieve a stable catheter position in the right atrial appendage. 
2.4 Methods 
2.4.1 Modified and Standard Surface 12-lead ECG Measurements 
The modified surface 12-lead ECG (where posterior leads V8 and V9 replaced leads V4 
and V6) was used in patients undergoing their AF ablation procedure without 
electroanatomical mapping guidance.  Standard 12-lead ECG placement was used in 
patients undergoing their procedures with electroanatomical mapping guidance since the 
external reference patches for the CARTO® 3 (Biosense Webster) and EnSite 
Velocity™ (St. Jude Medical) systems preclude placement of posterior leads V8 and 
V9.  The decision to use electroanatomical mapping was at the discretion of the 
physician and there were no significant differences in clinical characteristics between 
the two patient groups (Table 2.1).   
2.4.2 Surface AF Waveform Analysis 
AF Waveform Extraction – Principal Component Analysis 
The continuous AF waveform was extracted from the surface ECG using PCA as 
previously described by our group (Raine et al., 2004 and 2005 - Appendix 1).  This is a 
multi-variable technique commonly used to identify and separate different sources in 
the data based on their degree of correlation.  Mathematically it represents a linear 
transformation of the data to a new set of variables (principal components (PCs)), which 
are uncorrelated. 
The transformation is described by: 
𝑃𝑃𝑃𝑃1 = 𝑐𝑐1,1𝑙𝑙1 + 𝑐𝑐1,2𝑙𝑙2 ⋯𝑐𝑐1,12𝑙𝑙12 
𝑃𝑃𝑃𝑃2 = 𝑐𝑐2,1𝑙𝑙1 + 𝑐𝑐2,2𝑙𝑙2 ⋯𝑐𝑐2,12𝑙𝑙12 
⋮ 
𝑃𝑃𝑃𝑃12 = 𝑐𝑐12,1𝑙𝑙1 + 𝑐𝑐12,2𝑙𝑙2 ⋯𝑐𝑐12,12𝑙𝑙12 
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where PCi are the principal components, lj are the ECG leads and ci,j are the transform 
coefficients derived from the eigenvectors of the covariance matrix of the ECG leads 
arranged in order of descending eigenvalue.  The transform coefficients describe the 
contribution of each lead to the PCs.  In AF waveform analysis, the PCs contain the 
separated atrial, ventricular and noise components of the ECG signal (Figure 2.1).  For 
subsequent AF waveform analysis, a single PC was identified visually as the one 
containing the largest amplitude AF waveform (PCAF).  To quantify the contribution of 
each ECG lead to PCAF, we report the absolute value of the transform coefficients 
(�𝑐𝑐𝐴𝐴𝐴𝐴,𝑗𝑗�) separately for standard and modified 12-lead ECG configurations. 
AF Waveform Extraction – Average Beat QRST Subtraction 
As only one ECG configuration (standard or modified) was recorded in each patient, the 
AF waveform extracted from lead V1 using ABS (as described in Bollmann et al. and 
Holm et al. (1998)) was used as a control to allow comparisons of the strength of 
correlation between surface and intracardiac DAF measurements between the two ECG 
configurations. 
2.4.3 Intracardiac Waveform Analysis 
PCA and Fourier analysis were used to calculate the intracardiac DAF from each bipole 
on the catheters positioned in the CS, HRA and pulmonary vein ostia.  The most distal 
CS bipole (CS1-2) was excluded from the analysis because of the predominant 
ventricular activity and low amplitude atrial electrograms frequently recorded at this 
location. 
Dominant AF Frequency 
Power spectral density of the body surface and intracardiac atrial signals was performed 
by periodogram and the DAF was defined as the AF frequency with the highest power 
in the range 3-10Hz (Raine et al., 2004 and 2005).  Figure 2.2 shows a 10-second 
section of ECG lead V1 with the extracted AF waveform (PCA and ABS) and 
intracardiac recordings from the HRA and CS.  The corresponding frequency spectra 
and DAF are shown.  Surface and intracardiac DAF were analysed in consecutive 10-
second sections and mean values across the one-minute recordings are reported. 
2.4.4 Statistical Analyses 
Continuous variables are expressed as mean ± SD.  Patient characteristics were 
compared between the modified and standard ECG groups using Student’s independent 
t-test for continuous variables and Pearson’s chi-squared test for categorical variables.   
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Surface DAF calculated using PCA and ABS from modified and standard ECG 
configurations was correlated with intracardiac DAF using Pearson’s correlation.  
Fisher r-to-z transformation was used to evaluate the significance of the difference 
between comparable correlation coefficients.  All tests were 2-tailed and p<0.05 was 
considered statistically significant.  
2.5 Results 
2.5.1 Modified vs. Standard 12-lead ECG 
Surface DAF from both modified and standard 12-lead ECG configurations correlated 
strongly with intracardiac DAF in the HRA, CS and right-sided pulmonary veins with 
all correlations being significant at the 0.01 level (Tables 2.2 and 2.3).  Surface DAF 
from the standard but not the modified ECG correlated strongly with left upper 
pulmonary vein (LUPV) DAF (PCA r=0.79; ABS r=0.84, p<0.01 vs. PCA and ABS 
r=0.43, p<0.05).  In addition, there was only moderate correlation between surface DAF 
from either ECG configuration and left lower pulmonary vein (LLPV) DAF (modified 
r=0.43; standard r=0.50, p<0.05) (Tables 2.2 and 2.3).  In the ABS control group, 
surface DAF from the standard ECG had a significantly stronger correlation with LUPV 
DAF compared to the modified ECG (0.84 vs. 0.43; p<0.01) (Table 2.4).  In addition, 
surface DAF from the modified ECG had a stronger correlation with intracardiac DAF 
from HRA (0.91 vs. 0.82) and CS5-6 (0.81 vs. 0.62), although these did not reach 
statistical significance.  Therefore, the only significant difference between modified and 
standard ECG configurations in the PCA group was observed with CS7-8 where the 
modified ECG had a stronger correlation with intracardiac DAF compared to the 
standard ECG (0.89 vs. 0.74; p=0.03) (Table 2.4). 
2.5.2 ECG Lead Contribution to AF Principal Component 
We assessed the individual ECG lead contributions to the PCAF by plotting the absolute 
values of the transfer coefficients (�𝑐𝑐𝐴𝐴𝐴𝐴,𝑗𝑗�) for the modified and standard 12-lead ECG 
configurations (Figure 2.3).  Lead V1 contributed most to the PCAF in both ECG 
configurations, with a transfer coefficient typically three times that of the other leads.  
This is most likely a reflection of the large amplitude AF waveform typically seen in 
this lead. 
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2.6 Discussion 
To our knowledge, this study is the first to correlate surface DAF measurements 
calculated using PCA and Fourier analysis of a modified 12-lead ECG configuration 
(including posterior leads V8 and V9) with intracardiac DAF measurements from the 
high right atrium, coronary sinus and pulmonary vein ostia.  As we only recorded one 
ECG configuration (standard or modified) in each patient, we controlled for 
comparisons between the two by calculating surface DAF from lead V1 using ABS and 
Fourier analysis in all patients.  Surface DAF from both modified and standard ECG 
configurations correlated strongly with intracardiac DAF from the high right atrium, 
coronary sinus and right-sided pulmonary veins.  However, in general, there was only 
moderate correlation between surface DAF and intracardiac DAF from the left-sided 
pulmonary veins.   
Taking into account the results from the average beat subtraction (ABS) control group, 
the only significant difference in the strength of correlation with intracardiac DAF 
between the modified and standard ECG configurations in the PCA group was in a 
single bipolar recording from the proximal part of the coronary sinus (CS7-8), which is 
usually more reflective of right atrial activity.  Therefore, our results show that surface 
DAF calculated using PCA of a modified 12-lead ECG configuration (which included 
posterior leads V8 and V9) does not have a stronger correlation with left atrial activity 
compared to the standard 12-lead ECG.  This can be explained by the dominance of 
lead V1 in the AF principal component from both ECG configurations (Figure 2.3) on 
account of its characteristic large amplitude AF waveform.  This also explains the 
stronger correlation between surface DAF and intracardiac frequencies recorded from 
the right atrium and the strong correlation between surface DAF calculated using PCA 
(12-lead ECG) and ABS (lead V1) in both ECG configurations (modified: r=0.91; 
standard: r=0.86).  The disparity between our results and the findings of Petrutiu et al. 
(2009) can be explained by differences in the method used to extract the AF waveform 
from the surface ECG.  They used QRST subtraction on individual ECG leads, whereas 
we used PCA on 12-lead ECG configurations.  Whilst posterior lead V9 may have the 
strongest correlation with left atrial activity, its relatively small amplitude AF waveform 
ensures that it does not contribute significantly to the AF principal component in PCA. 
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2.7 Limitations 
Firstly, we did not record both ECG configurations in each patient.  However, we 
calculated surface DAF from lead V1 using ABS and Fourier analysis in all patients as a 
control measure to validate comparisons between the modified and standard ECG 
groups.  Secondly, we only used recordings from the coronary sinus and pulmonary 
vein ostia to reflect left atrial activity.  Previous studies have shown that the physical 
and electrical connections between the coronary sinus and left atrium can vary between 
patients (Antz et al., 1998; Chauvin et al., 2000) and so coronary sinus recordings may 
not reflect left atrial activity accurately in all cases (Ndrepepa et al., 2001).  Similarly, 
other areas of the left atrium such as the left atrial appendage, roof, septum and 
posterior wall commonly contain high frequency sites and were not sampled in this 
study.  These sites may contribute to the surface DAF and therefore merit further study.  
2.8 Conclusions 
Surface DAF calculated using PCA and Fourier analysis of a modified 12-lead ECG 
configuration (which included posterior leads V8 and V9) does not have a stronger 
correlation with left atrial activity when compared to the standard 12-lead ECG.  
Surface DAF from both modified and standard ECG configurations correlate strongly 
with right atrial activity, reflecting the dominance of lead V1 in the AF principal 
component.
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Table 2.1: Patient Characteristics. 
* P value from independent t-test (continuous variables) or chi-squared test (categorical variables) comparing modified and standard ECG 
configurations.  LA = left atrial; LVEF = left ventricular ejection fraction. 
 
 Whole Group (n=96) Modified ECG (n=51) Standard ECG (n=45) P Value* 
Age (years) 57.1 ± 10.1 56.1 ± 11.1 58.2 ± 9.1 0.30 
Male Gender 76 (79%) 40 (78%) 36 (80%) 1 
Persistent AF 52 (54%) 24 (47%) 28 (62%) 0.16 
AF History (years) 4.3 ± 4.2 4.0 ± 3.8 4.6 ± 4.8 0.54 
LA Volume (ml) 60 ± 21 59 ± 20 61 ± 22 0.75 
LVEF (%) 53 ± 5 53 ± 6 53 ± 5 0.77 
Hypertension 35 (36%) 14 (27%) 21 (47%) 0.06 
Diabetes 8 (8%) 5 (10%) 3 (7%) 0.72 
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Table 2.2: Surface and Intracardiac DAF Correlation: Modified 12-lead ECG configuration 
a Correlation is significant at the 0.01 level (2-tailed); b Correlation is significant at the 0.05 level (2-tailed) 
ABS = average beat subtraction, CS = coronary sinus; DAF = dominant AF frequency; HRA = high right atrium; LCPV = left common pulmonary 
vein; LLPV = left lower pulmonary vein; LUPV = left upper pulmonary vein; PCA = principal component analysis; RLPV = right lower pulmonary 
vein; RUPV = right upper pulmonary vein 
 
12-lead ECG 
Configuration 
Surface DAF (Hz) 
PCA 
Surface DAF (Hz) 
ABS 
Surface DAF 
R Value 
Intracardiac DAF (Hz) R Value 
PCA 
R Value 
ABS 
Modified (n=51) 6.52 ± 1.07 6.51 ± 1.13 0.91 
HRA 6.54 ± 1.19 0.92a 0.91a 
CS3-4 6.04 ± 0.97 0.81a 0.78a 
CS5-6 6.11 ± 0.93 0.87a 0.81a 
CS7-8 6.06 ± 0.90 0.89 a 0.83a 
CS9-10 6.01 ± 0.99 0.80a 0.76a 
LUPV 6.07 ± 0.87 0.43b 0.43b 
LLPV 6.10 ± 0.83 0.43b 0.43b 
LCPV 6.75 ± 0.83 0.88a 0.73b 
RUPV 5.90 ± 0.86 0.69a 0.62a 
RLPV 5.84 ± 1.00 0.72a 0.69a 
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Table 2.3: Surface and Intracardiac DAF Correlation: Standard 12-lead ECG configuration 
a Correlation is significant at the 0.01 level (2-tailed); b Correlation is significant at the 0.05 level (2-tailed) 
Abbreviations as for Table 2.2 
 
 
 
12-lead ECG 
Configuration 
Surface DAF (Hz) 
PCA 
Surface DAF (Hz) 
ABS 
Surface DAF 
R Value 
Intracardiac DAF (Hz) R Value 
PCA 
R Value 
ABS 
Standard (n=45) 6.13 ± 0.86 6.24 ± 0.65 0.86 
HRA 6.28 ± 0.86 0.86a 0.82a 
CS3-4 5.69 ± 0.57 0.69a 0.68a 
CS5-6 5.66 ± 0.69 0.69a 0.62a 
CS7-8 5.65 ± 0.60 0.74a 0.73a 
CS9-10 5.70 ± 0.71 0.78a 0.78a 
LUPV 6.07 ± 0.80 0.79a 0.84a 
LLPV 6.06 ± 0.81 0.50b 0.50b 
RUPV 5.72 ± 0.64 0.62a 0.56a 
RLPV 5.60 ± 0.79 0.72a 0.71a 
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Table 2.4: Correlation Coefficient Comparison: Modified vs. Standard ECG Configuration 
Z and P values were calculated using the Fisher r-to-z transformation 
Abbreviations as for Table 2.2 
Intracardiac 
Channel 
PCA   ABS   
Modified ECG Standard ECG   Modified ECG Standard ECG   
R Value Z Value P Value R Value Z Value P Value 
HRA 0.92 0.86 1.33 0.18 0.91 0.82 1.70 0.09 
CS3-4 0.81 0.69 1.23 0.22 0.78 0.68 0.99 0.32 
CS5-6 0.87 0.69 2.18 0.03 0.81 0.62 1.82 0.07 
CS7-8 0.89 0.74 2.19 0.03 0.83 0.73 1.15 0.25 
CS9-10 0.80 0.78 0.21 0.83 0.76 0.78 -0.31 0.76 
LUPV 0.43 0.79 -2.25 0.02 0.43 0.84 -2.80 <0.01 
LLPV 0.43 0.50 -0.31 0.76 0.43 0.50 -0.31 0.76 
RUPV 0.69 0.62 0.46 0.65 0.62 0.56 0.35 0.73 
RLPV 0.72 0.72 0.00 1.00 0.69 0.71 -0.14 0.89 
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Figure 2.1: Principal Component Analysis. Left panel: 12-lead ECG showing AF.  
Right panel: Twelve principal components (PCs) derived from the 12-lead ECG.  The 
ventricular components are predominantly contained in the upper PCs (1-3).  The 
largest amplitude AF waveform is seen in PC6 (black box).  The lower PCs (9-12) 
contain electrical noise.  The amplitude scale is different for each PC with PC1 having 
the largest amplitude and PC12 the smallest.
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Figure 2.2: Ten-second section of ECG lead V1 with extracted AF waveform (PCA and ABS) and intracardiac recordings from HRA and CS.  
Corresponding frequency spectra and DAF are shown.  Abbreviations as for Table 2.2 
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 Figure 2.3: ECG Lead contribution to AF Principal Component for Modified and 
Standard 12-lead configurations. Minimum, first quartile, median, third quartile and 
maximum principal component contribution are shown for each ECG lead.  Outliers and 
extreme outliers are represented by black circles and stars respectively and are labelled 
by case number.
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Chapter 3.  Prediction of catheter ablation outcome using surface ECG 
waveform and clinical parameters in patients with atrial fibrillation 
3.1 Abstract 
Background 
Previous studies assessing the value of surface AF waveform parameters in predicting 
ablation outcome have produced conflicting results.  The aim of this study was to 
evaluate whether a combination of surface AF and clinical parameters prior to ablation 
could predict acute and 12-month outcome afterwards. 
Methods 
Patients with symptomatic AF undergoing catheter ablation were recruited.  Surface 
ECG recordings were analysed at the start and end of the procedure.  The AF waveform 
was extracted using principal component analysis.  Waveform parameters: fibrillatory 
wave amplitude (FWA), spatial organisation, dominant AF frequency (DAF), spectral 
concentration and sample entropy were studied.  All patients underwent pulmonary vein 
isolation (PVI).  Additional left atrial ablation was considered in patients who remained 
in AF after PVI.  Surface AF and clinical parameters (gender, AF type and history, left 
atrial volume, LVEF, hypertension and diabetes) were correlated retrospectively with 
ablation outcomes. 
Results 
96 consecutive patients (52 persistent AF) were studied.  In multivariate analysis, the 
acute outcome risk score had a predictive accuracy of 93% with paroxysmal AF and 
spectral concentration both independent predictors of AF termination during ablation 
(p<0.001).  Paroxysmal AF (p<0.01), lead V9 FWA and male gender (p=0.02) were 
independent predictors of sinus rhythm maintenance 12-months after ablation.  
Inclusion of the change in lead V9 FWA after ablation (p=0.02) increased the predictive 
accuracy of the 12-month outcome risk score from 79% to 88%. 
Conclusion 
Multivariate risk scores comprising surface AF and clinical parameters prior to ablation 
can predict acute and 12-month outcomes in patients with AF. 
  
 42 
3.2 Introduction 
The threshold for recommending catheter ablation to patients with symptomatic AF has 
fallen progressively over the past ten years (Wazni et al., 2005; Tanner et al., 2011).  
Pulmonary vein isolation (PVI) is the mainstay of catheter ablation for AF and can 
achieve durable sinus rhythm in 59-93% of patients with paroxysmal AF (Oral et al., 
2003; Van Belle et al., 2008; Fiala et al., 2008).  However, success rates in patients with 
persistent AF remain significantly lower, despite the development of ablation strategies 
aimed at modifying the AF substrate more extensively (Brooks et al., 2010).   
It is widely accepted that the atrial waveform seen on the surface ECG during AF 
reflects intracardiac electrical activity (Alcaraz et al., 2011; Petrutiu et al., 2009).  Our 
group has developed and validated a method of extracting the AF waveform from the 
surface ECG using principal component analysis (PCA) (Langley et al., 2006; Raine et 
al., 2004 and 2005 - Appendix 1).  The main advantage of PCA over the more 
commonly used QRST subtraction method is that it derives a global atrial signal from 
all 12 ECG leads (Figure 2.1). 
To date, several studies have assessed the value of individual surface AF parameters in 
predicting ablation outcomes with conflicting results.  In a study of patients with 
persistent AF, Matsuo et al. (2009) reported that mean surface AF cycle length >142ms 
was predictive of AF termination during ablation and longer-term maintenance of sinus 
rhythm.  In contrast, Garibaldi et al. (2012) reported that higher spectral concentration 
(reflecting a more organised AF waveform) but not DAF (the inverse of mean AF cycle 
length) was predictive of maintenance of sinus rhythm following ablation.  Nault et al. 
(2009) reported that higher fibrillatory wave amplitude (FWA) predicted AF 
termination during ablation and longer-term freedom from arrhythmia.  However, Meo 
et al. (2013) reported that AF termination during ablation could be predicted using a 
logistic regression model combining FWA and AF spatiotemporal variability but not by 
FWA alone.  In light of these discordant results, the aim of this study was to establish 
whether a combination of surface AF and clinical parameters prior to ablation could 
predict acute and 12-month outcome afterwards. 
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3.3 Methods 
3.3.1 Patient Recruitment and Ethical Approval 
This study was based on the same cohort of 96 patients described in Chapter 2 (sections 
2.3.1 and 2.3.2). 
 3.3.2 Study and Ablation Protocol 
A surface 12-lead ECG was recorded throughout the ablation procedure on a Labsystem 
Pro™ system (Bard EP) at a digital sampling rate of 1000Hz for offline analysis in 
Matlab®2013.  At the start of the procedure, a two-minute ECG recording was analysed 
from patients in AF.  For patients in sinus rhythm, AF induction was attempted using 
routine pacing manoeuvres.  If AF was successfully induced, a 5-minute recording was 
collected to allow the arrhythmia to stabilise and AF parameters from the final two 
minutes were analysed.  Patients were excluded from the study if AF could not be 
initiated or did not sustain for at least 5 minutes.  Additional two-minute ECG 
recordings prior to AF termination or electrical cardioversion were analysed to assess 
the effect of ablation on surface AF waveform parameters. 
Pulmonary Vein Isolation  
All patients underwent PVI using one of three ablation technologies: (1) PVAC™ 
multielectrode circumferential ablation catheter (Medtronic Ablation Frontiers), (2) 
Arctic Front® Advance™ cryoballoon (Medtronic CryoCath), or (3) Wide-area 
circumferential ablation guided by the CARTO® 3 cardiac mapping system (Biosense 
Webster).  Electrical isolation of the pulmonary veins was confirmed using standard 
pacing manoeuvres.  
Left Atrial Substrate Ablation 
Additional complex fractionated atrial electrogram (CFAE) and/or linear ablation was 
added in patients who remained in AF after PVI, according to the degree of signal 
complexity and fractionation in the left atrium. 
CFAE Ablation 
A detailed analysis of the left atrium and inter-atrial septum was performed to identify 
CFAEs (focal sites exhibiting constant electrical activity or multicomponent 
electrograms with cycle length ≤120ms averaged over a 10-second period), which were 
then ablated. This process was completed when no residual CFAE sites could be 
identified or when sinus rhythm was restored by ablation. 
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Linear Ablation 
A combination of ‘roof line’ (connecting right and left upper pulmonary vein ostia), 
‘mitral line’ (connecting left lower pulmonary vein ostium to mitral valve annulus), and 
‘inferior line’ (connecting right lower pulmonary vein to coronary sinus) were 
constructed depending on the degree of signal complexity in each region.  Linear 
ablation was performed until electrograms were no longer recordable or double 
potentials were evident along the length of each line.  Differential pacing manoeuvres 
were not performed routinely to further confirm conduction block.  All patients in AF at 
the end of the ablation procedure underwent electrical cardioversion.  
3.3.3 Modified Surface 12-lead ECG Measurements 
It was initially planned to record a 15-lead ECG (including posterior leads V7-9) since 
posterior leads have been shown to reflect left atrial activity better than the standard 12-
lead ECG configuration (Petrutiu et al., 2009).  However, because the amplifier 
available could only incorporate 12 ECG lead inputs, we opted for a modified surface 
12-lead ECG (where posterior leads V8 and V9 replaced leads V4 and V6) in patients 
undergoing their AF ablation procedure when electroanatomical mapping was not being 
used.  Standard 12-lead ECG placement was used in patients undergoing procedures 
when electroanatomical mapping was deployed, since the external reference patches for 
the CARTO® 3 (Biosense Webster, Inc.) and EnSite Velocity™ (St. Jude Medical, 
Inc.) systems preclude placement of posterior leads V8 and V9.  The decision to use 
electroanatomical mapping was at the discretion of the physician and there were no 
significant differences in clinical characteristics between the two patient groups (Table 
2.1).  As reported in Chapter 2, we observed no difference in the strength of correlation 
between modified or standard 12-lead ECG configurations and intracardiac recordings 
from the left and right atrium (Raine et al., 2015). 
3.3.4 Surface AF Waveform Analysis 
The ECG recordings were analysed for five parameters previously used by others to 
characterise body surface AF signals: (1) fibrillatory wave amplitude (FWA); (2) spatial 
organisation; (3) dominant AF frequency (DAF); (4) spectral concentration and (5) 
sample entropy.  FWA and spatial organisation were calculated directly from isolated 
TQ sections of the ECG, whereas DAF, spectral concentration and sample entropy were 
calculated from the continuous AF waveform extracted from the 12-lead ECG.  The 
continuous AF waveform was extracted from the surface ECG using PCA as previously 
described in Section 2.4.2. 
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3.3.5 AF Waveform Parameters 
The five AF waveform parameters included in this study are described below:  
1. Fibrillatory Wave Amplitude (FWA) 
FWA reflects the mass of atrial tissue activated during AF and is therefore dependent on 
the amount of viable atrial myocardium.  Therefore, patients with more extensive atrial 
fibrosis would be expected to have lower FWA than those with near normal atria.  In 
this study, AF amplitude was determined from the TQ sections of the ECG - sections 
containing only atrial activity and free from obscuring ventricular activity.  FWA was 
calculated as the mean peak-to-peak amplitude of the AF waveform in TQ sections 
containing at least one AF cycle length from all 12 leads in both ECG configurations 
(Figure 3.1). 
2. Spatial Organisation 
Spatial organisation quantifies the degree of similarity in AF waveforms measured at 
different body surface sites (Di Marco et al., 2012; Bonizzi et al., 2010).  As previously 
reported, PCA was applied to TQ sections of the 12-lead ECG recordings and the 
percentage of AF waveform variability explained by the first three principal 
components calculated (Di Marco et al., 2012).  Recordings with highly correlated AF 
waveforms across the 12 ECG leads, and hence high spatial organisation, would have a 
high percentage of variability explained by these three principal components. 
3. Dominant AF Frequency (DAF) 
Fourier analysis was applied to the continuous AF waveform extracted from the ECG to 
calculate the power spectral density by periodogram with rectangular window and 
frequency resolution of 0.1Hz.  The DAF was defined as the AF frequency with the 
highest power in the range 3-10Hz as in our previous studies (Raine et al., 2004 and 
2005). 
4. Spectral Concentration 
Spectral concentration measures the concentration of power around the DAF relative to 
the whole recorded spectrum.  In this study, spectral concentration was calculated from 
the power spectral density as the ratio of power contained in the interval DAF ± 0.5Hz 
to the power contained in the interval 3 to 10Hz (Di Marco et al., 2012).  A single stable 
AF source would give rise to an AF spectrum with a single narrow peak, indicating that 
the majority of spectral energy was concentrated around the DAF (i.e. high spectral 
concentration).   
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Conversely, multiple and/or temporally unstable AF sources have AF spectra with 
multiple peaks or diffuse energy around the dominant peak (i.e. low spectral 
concentration). 
5. Sample Entropy 
Sample entropy is a marker of the complexity and irregularity of atrial activity with 
higher values indicating more disorganised activity (Alcaraz and Rieta, 2009).  It is 
defined as the negative natural logarithm of the conditional probability that two 
sequences of data values, that are similar for m points, will remain similar at the next 
point in the data sequence, within a tolerance r.  Thus sample entropy (r,m) = -ln (A/B), 
where A and B are the total number of forward matches of length m+1 and m, 
respectively.  Our approach follows that of Alcaraz and Rieta (2009) who applied 
sample entropy to the mean atrial waveform, derived by narrow band filtering the 
continuous AF waveform around the DAF (DAF ± 1.5Hz).  Values of m=2 and r=0.25 
times the standard deviation of the atrial waveform were used as they have previously 
produced accurate and reproducible sample entropy results (Alcaraz and Rieta, 2009).  
Each of the AF waveform parameters were analysed in consecutive 10-second sections 
and mean values across the 2-minute ECG recordings are reported. 
3.3.6 Clinical Parameters 
Ablation outcome was correlated with the following clinical parameters: gender, AF 
type (paroxysmal / persistent), total duration of AF history, left atrial volume, left 
ventricular ejection fraction (calculated using Simpson’s biplane method from apical 
two and four-chamber views on transthoracic echocardiography performed at the initial 
outpatient consultation prior to ablation), comorbidities of hypertension and diabetes. 
3.3.7 Clinical Outcome following Ablation 
Acute Outcome 
Acute outcome was assessed by cardiac rhythm at the end of the ablation procedure 
(prior to electrical cardioversion if performed): (1) Sinus rhythm; (2) AF. 
Twelve-month Outcome 
Clinical outcome was determined by symptom review, 12-lead ECG and 72-hour Holter 
monitoring at the twelve month assessment after ablation and was divided into two 
categories: (1) Sinus rhythm (no arrhythmia symptoms and no documented AF episodes 
>30 seconds); (2) AF recurrence (documented AF episodes >30 seconds). 
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3.3.8 Statistical Analyses 
Continuous variables are expressed as mean ± SD.  Baseline surface AF parameters and 
clinical variables were compared between acute and 12-month outcome groups using 
Student’s independent t-test for continuous variables and Pearson’s chi-squared test for 
categorical variables.  The magnitude of change in surface AF parameters after ablation 
in those who remained in AF was compared between acute and 12-month outcome 
groups using independent t-tests.  Acute and 12-month outcome were compared 
between different ablation strategies using Fisher’s exact test.  All tests were 2-tailed 
and p<0.05 was considered statistically significant.   
Parameters with p≤0.10 were entered into a binary logistic regression model using 
stepwise selection to assess their independent and combined ability to predict acute and 
12-month outcome following ablation. After multivariate analysis, parameters with 
p≤0.10 were retained and risk scores calculated by multiplying the maximum likelihood 
estimates with the values for each parameter included in the model.  Binary values were 
used for categorical variables.  ROC curve analysis was used to evaluate the 
performance of independent outcome predictors and multivariate risk scores and to 
select cut-off points with highest sensitivity and specificity. 
3.4 Results 
Baseline characteristics of the 96 consecutive patients recruited to the study are shown 
in Table 2.1.  There were no significant differences in clinical characteristics between 
the modified and standard ECG groups.  In addition, there were no significant 
differences in acute procedural outcome between patients treated with PVI alone or 
additional lesions after pulmonary vein isolation (‘PVI-plus’) (Table 3.1).  In patients 
with paroxysmal AF, 28/36 (78%) treated with PVI alone maintained sinus rhythm 12-
months after ablation compared to 2/8 (25%) treated with more extensive lesion sets.  In 
contrast, there was no significant difference in 12-month outcome in patients with 
persistent AF treated with PVI alone or PVI-plus (Table 3.1). 
3.4.1 Surface AF Waveform & Clinical Parameters and Acute Outcome 
Sinus rhythm was restored during ablation in 17/44 (39%) patients with paroxysmal AF 
but in only one patient with persistent AF (p<0.001) (Table 3.2).  Left ventricular 
ejection fraction was significantly higher in those who reverted to sinus rhythm during 
ablation compared to those who remained in AF (54 ± 2 vs. 53 ± 6%; p=0.02).   
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Spatial organisation (96.6 ± 1.5% vs. 94.3 ± 3.1%; p<0.001), spectral concentration 
(41.0 ± 7.6% vs. 36.2 ± 8.2%, p=0.03) and FWA in lead II (0.123 ± 0.035mV vs. 0.100 
± 0.036mV; p=0.02) were significantly higher in patients who reverted to sinus rhythm 
during ablation (Table 3.3). Furthermore, patients who reverted to sinus rhythm during 
ablation had a significantly greater increase in FWA in lead II compared to those who 
remained in AF (0.012 ± 0.029mV vs. -0.005 ± 0.021mV; p=0.03) (Table 3.3).  
Conversely, baseline DAF was significantly lower in patients who reverted to sinus 
rhythm (5.5 ± 0.6Hz vs. 6.5 ± 1.0Hz, p<0.001).      
In multivariate analysis (Table 3.4), paroxysmal AF (OR 0.01, 95% CI <0.01-0.12; 
p<0.001) and spectral concentration (OR 1.17, 95% CI 1.05-1.31; p<0.001) were 
independent predictors of AF termination during ablation.  The area under the receiver 
operating characteristic (ROC) curve for the multivariate risk score to predict acute 
procedural outcome was 0.93 (95% CI 0.87-0.99; p<0.001) (Figure 3.2).  There were no 
significant differences in the other surface AF and clinical parameters studied including 
the degree of change after ablation between patients who reverted to sinus rhythm and 
those who remained in AF (Tables 3.2 and 3.3). 
3.4.2 Surface AF Waveform & Clinical Parameters and Twelve Month Outcome 
Twelve months after ablation, 56 (58%) patients maintained sinus rhythm without 
further intervention (68% paroxysmal and 50% persistent AF; p=0.10).  Men were more 
likely to maintain sinus rhythm than women (64% vs. 35%; p=0.02).  In the modified 
ECG group, patients maintaining sinus rhythm had significantly greater FWA in 
posterior lead V9 before ablation (0.052 ± 0.025mV vs. 0.041 ± 0.015mV; p=0.05) and 
showed a greater reduction in that measure after ablation (-0.004 ± 0.009mV vs. 0.003 ± 
0.008mV; p<0.01) compared to those with recurrent AF (Table 3.3).   
In multivariate analysis of baseline surface AF and clinical parameters (Table 3.4), 
paroxysmal AF (OR 0.12, 95% CI 0.03-0.55; p<0.01), FWA in lead V9 (OR >999; 
p=0.02) and male gender (OR 0.10, 95% CI 0.01-0.75; p=0.02) were independent 
predictors of maintenance of sinus rhythm after ablation.  Furthermore, inclusion of the 
change in FWA in lead V9 after ablation (OR <0.001; p=0.02) increased the predictive 
accuracy of the multivariate risk score from 79% to 88% (Table 3.4).  ROC curve 
analyses for the multivariate risk scores to predict outcome 12-months after ablation are 
shown in Figure 3.3. 
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3.5 Discussion 
3.5.1 Main Findings 
To our knowledge, the present study is the most comprehensive evaluation to date of the 
association between surface AF waveform and clinical parameters prior to ablation and 
arrhythmia outcomes afterwards in a cohort of patients with either paroxysmal or 
persistent AF.  The main finding is that multivariate risk scores comprising surface AF 
and clinical parameters prior to ablation can accurately predict acute and 12-month 
outcome afterwards in this diverse patient group.  Paroxysmal AF and spectral 
concentration were independent predictors of AF termination during the ablation 
procedure.  Paroxysmal AF, FWA in lead V9 and its change after ablation, and male 
gender were independent predictors of maintenance of sinus rhythm 12 months after 
ablation. 
3.5.2 Ablation Outcome 
Ablation Strategy 
In this study, 58% of patients maintained sinus rhythm 12 months after a single ablation 
procedure (68% paroxysmal vs. 50% persistent AF), which is comparable to the results 
of others (Ganesan et al., 2013).  78% of patients with paroxysmal AF treated with PVI 
alone maintained sinus rhythm 12 months after ablation compared to 25% of patients 
treated with PVI and additional left atrial substrate ablation.  This supports the strategy, 
previously advocated by others (Mun et al., 2012; Wu et al., 2013), of performing PVI 
alone as a first procedure in patients with paroxysmal AF – even if sinus rhythm is not 
restored during ablation.  This contrasts with the lack of difference in 12-month 
outcome in patients with persistent AF treated with PVI alone or PVI-plus, which 
concurs with the results of the STAR AF II trial (Verma et al., 2015).  
Surface AF Waveform parameters 
Spectral concentration was an independent predictor of acute outcome with higher 
values correlating with AF termination during ablation, as shown by others (Garibaldi et 
al., 2012).  However, Garibaldi et al. also reported an association between spectral 
concentration and medium term outcome following ablation, not corroborated by our 
study.  Fibrillatory wave amplitude in posterior ECG lead V9 was an independent 
predictor of 12-month outcome in this study with higher values associated with 
maintenance of sinus rhythm long-term.  This is a novel finding and highlights the 
benefit of including posterior ECG leads in surface AF waveform analysis on account of 
their stronger correlation with left atrial activity (Petrutiu et al., 2009).   
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The association between higher FWA values and freedom from arrhythmia recurrence 
after ablation has been reported previously by Nault et al. (2009); although, we could 
not confirm the correlation between FWA in lead V1 and ablation outcome they 
reported.  This may be due to the fact that they calculated FWA manually from a single 
ECG lead whereas we used a computer assisted algorithm to calculate FWA.  In 
addition, 26% of their patients were taking amiodarone with its associated effects on 
cardiac electrophysiology.  Reduction in lead V9 FWA after ablation was also identified 
as an independent predictor of maintenance of sinus rhythm at 12 months.  This 
correlation between FWA reduction after ablation and arrhythmia freedom has been 
previously reported by Meo et al. (2012) and likely reflects successful ablation of atrial 
myocardium critical to the maintenance of AF.  
In this study, baseline DAF was associated with acute but not 12-month outcome with 
significantly lower values in patients who reverted to sinus rhythm during ablation, as 
reported by Heist et al. (2012).  There was no significant difference in the magnitude of 
DAF reduction after ablation between patients who maintained sinus rhythm and those 
with recurrent AF, in contrast to Yoshida et al. (2010) who reported that an 11% 
reduction in lead V1 DAF predicted maintenance of sinus rhythm after ablation.  The 
discordance in results is likely secondary to the differing study populations, ablation 
strategy and method of DAF calculation from the surface ECG.  Finally, sample entropy 
was not predictive of acute or 12-month outcome after ablation, corroborating the 
findings of Garibaldi et al. (2012). 
Clinical parameters 
In multivariate analysis, paroxysmal AF was an independent predictor of both acute and 
12-month outcome following ablation, as shown by other studies (Wokhlu et al., 2010a; 
Balk et al., 2010; D'Ascenzo et al., 2013).  15/18 (83%) patients with AF termination 
during ablation maintained sinus rhythm at 12 months, corroborating the findings of 
Komatsu et al. (2012) that termination of AF during ablation is a predictor of favourable 
longer-term outcome.  In this study, male gender was an independent predictor of sinus 
rhythm maintenance 12 months after ablation, as shown by Heist et al. (2012).  
However, there was no significant correlation between left atrial volume and ablation 
outcome at either time-point, in contrast to D'Ascenzo et al. (2013) and Ejima et al. 
(2014).  This disparity may be due to progressive atrial dilatation occurring in the 
variable interval between echocardiographic measurement and the ablation procedure 
itself, particularly in patients with persistent AF.   
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Finally, there were no significant differences between acute and 12-month outcome 
groups with respect to duration of AF history, left ventricular ejection fraction and 
prevalence of treated hypertension and diabetes, as reported by Ejima et al. (2014).   
3.6 Limitations 
Firstly, our analysis is limited by its relatively small sample size and the offline 
retrospective nature of the AF waveform analyses.  In addition, lead V9 FWA could 
only be calculated in the modified ECG group and therefore, the positive association 
between lead V9 FWA and twelve month ablation outcome was based on a smaller 
number of patients (n=51) rather than the whole cohort (n=96).  The predictive accuracy 
of these findings now needs to be tested prospectively in a separate group of patients.  
Secondly, although reflective of current clinical practice, the conduct of the AF ablation 
procedure was not standardised.  The optimum ablation strategy and extent of ablation 
required in patients with persistent AF has yet to be defined.  Thirdly, AF recurrence 
was determined by patients’ symptoms, 12-lead ECG and 72-hour Holter monitoring 12 
months after ablation and not by continuous ECG monitoring throughout the follow-up 
period.  Although, we cannot completely exclude asymptomatic AF episodes in the 
‘sinus rhythm’ group, we consider this unlikely given the previously high AF symptom 
burden in those studied. 
3.7 Conclusions 
Frequency and organisation parameters of AF waveform can readily be measured from 
the surface ECG and allow objective characterisation of AF.  Using routinely available 
surface AF waveform and clinical parameters, these results show that acute and longer-
term outcomes following ablation can be predicted by multivariate individualised 
patient profiling.  Predictive accuracy of ablation outcome was improved by including 
AF waveform parameters in comparison to when only clinical parameters were studied.  
If employed routinely, AF-waveform analysis would allow those most likely to benefit 
from ablation to be identified beforehand and so improve patient selection.
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Table 3.1: Additional Ablation Strategies and Clinical Outcome 
* P value from Fisher’s exact test comparing acute and 12-month outcome between the four ablation strategies 
 
 
 Acute Outcome 12-month Outcome 
SR AF P Value* SR AF P Value* 
Paroxysmal AF (n=44) 17 27  30 14  
PVI 17 19 
0.11 
28 8 
0.01 
PVI + Linear Ablation 0 4 1 3 
PVI + CFAE Ablation 0 2 1 1 
PVI + Linear + CFAE Ablation 0 2 0 2 
Persistent AF (n=52) 1 51  26 26  
PVI 1 10 
0.40 
5 6 
0.48 
PVI + Linear Ablation 0 18 7 11 
PVI + CFAE Ablation 0 13 7 6 
PVI + Linear + CFAE Ablation 0 10 7 3 
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Table 3.2: Univariate Analysis: Clinical Variables and Ablation Outcome 
  
 Acute Outcome 12-month Outcome 
SR AF P Value SR AF P Value 
Number of Patients 18 78  56 40  
Age (years) 56.6 ± 13.2 57.2 ± 9.5 0.83 56.7 ± 11.0 57.6 ± 9.0 0.67 
Male Gender 14 (78%) 62 (80%) 1 49 (88%) 27 (68%) 0.02 
Persistent AF  1 (6%) 51 (65%) <0.001 26 (46%) 26 (65%) 0.10 
AF History (years) 3.9 ± 2.6 4.4 ± 4.6 0.61 4.2 ± 4.3 4.4 ± 4.3 0.85 
LA Volume (ml) 55 ± 22 61 ± 21 0.30 59 ± 19 61 ± 24 0.81 
LVEF (%) 54 ± 2 53 ± 6 0.02 54 ± 4 52 ± 7 0.07 
Hypertension 7 (39%) 28 (36%) 1 20 (36%) 15 (38%) 1 
Diabetes 2 (11%) 6 (8%) 0.64 4 (7%) 4 (10%) 0.72 
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Table 3.3: Univariate Analysis: Surface AF Parameters and Ablation Outcome.  Lead V9 FWA could only be calculated in the Modified ECG group.  
The number and distribution of patients in this group is highlighted in red.  
 Acute Outcome 12-month Outcome 
SR AF P Value SR AF P 
Value 
Number of Patients 18 (n=12) 78 (n=39)  56 (n=31) 40 (n=20)  
Baseline       
Dominant AF Frequency (Hz) 5.5 ± 0.6 6.5 ± 1.0 <0.001 6.3 ± 1.2 6.4 ± 0.8 0.94 
Spectral Concentration (%) 41.0 ± 7.6 36.2 ± 8.2 0.03 37.3 ± 7.8 36.8 ± 9.0 0.80 
Spatial Organisation (%) 96.6 ± 1.5 94.3 ± 3.1 <0.001 95.2 ± 2.7 94.0 ± 3.3 0.07 
Sample Entropy 0.082 ± 0.018 0.087 ± 0.015 0.19 0.088 ± 0.017 0.085 ± 0.014 0.39 
Mean 12-lead ECG FWA (mV) 0.101 ± 0.027 0.087 ± 0.029 0.07 0.089 ± 0.028 0.090 ± 0.031 0.91 
Lead II FWA (mV) 0.123 ± 0.035 0.100 ± 0.036 0.02 0.105 ± 0.035 0.103 ± 0.039 0.75 
Lead V1 FWA (mV) 0.142 ± 0.058 0.123 ± 0.056 0.22 0.125 ± 0.051 0.129 ± 0.065 0.80 
Lead V9 FWA (mV) (n=51) 0.050 ± 0.018 0.047 ± 0.023 0.60 0.052 ± 0.025 0.041 ± 0.015 0.05 
Change after Ablation       
Dominant AF Frequency (Hz) -0.3 ± 0.4 -0.3 ± 0.4 0.92 -0.3 ± 0.4 -0.3 ± 0.4 0.39 
Spectral Concentration (%) 2.5 ± 8.2 0.2 ± 6.4 0.29 0.3 ± 6.9 0.6 ± 6.4 0.84 
Spatial Organisation (%) -0.3 ± 1.3 0.1 ± 1.6 0.44 -0.1 ± 1.6 0.2 ± 1.4 0.44 
Sample Entropy -0.001 ± 0.013 0.001 ± 0.011 0.83 -0.001 ± 0.013 0.001 ± 0.009 0.50 
Mean 12-lead ECG FWA (mV) 0.001 ± 0.008 -0.004 ± 0.023 0.56 -0.002 ± 0.021 -0.007 ± 0.023 0.35 
Lead II FWA (mV) 0.012 ± 0.029 -0.005 ± 0.021 0.03 -0.004 ± 0.019 -0.003 ± 0.027 0.82 
Lead V1 FWA (mV) 0.005 ± 0.022 -0.001 ± 0.059 0.74 0.004 ± 0.059 -0.006 ± 0.052 0.43 
Lead V9 FWA (mV) (n=51) 0.001 ± 0.005 -0.001 ± 0.010 0.71 -0.004 ± 0.009 0.003 ± 0.008 <0.01 
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Table 3.4: Multivariate Risk Scores to predict Ablation Outcome 
* Cumulative Predictive Accuracy = percentage of the study cohort in whom ablation outcome was correctly predicted.
 Parameter Maximum 
Likelihood 
Estimate 
Standard 
Error 
Wald 
Chi-
square 
P 
Value 
Odds 
Ratio 
Estimate 
95% CI for 
Odds Ratio 
Cumulative 
Predictive 
Accuracy* 
Acute Outcome Paroxysmal AF -4.82 1.36 12.49 <0.001 0.01 <0.01 - 0.12 80% 
Spectral Concentration 0.16 0.06 7.87 <0.001 1.17 1.05 - 1.31 92% 
Lead II FWA 17.52 10.25 2.92 0.09 >999.99 0.08 - >999.99 93% 
12-month Outcome  
(Baseline Parameters only) 
Paroxysmal AF -2.09 0.76 7.55 <0.01 0.12 0.03 - 0.55 67% 
Lead V9 FWA 46.75 20.19 5.36 0.02 >999.99 >999.99 74% 
Male Gender -2.28 1.01 5.05 0.02 0.10 0.01 - 0.75 79% 
12-month Outcome 
(Baseline Parameters and 
Change after Ablation) 
Change in Lead V9 FWA -270.1 111.7 5.84 0.02 <0.001 <0.001 75% 
Paroxysmal AF -1.97 0.90 4.84 0.03 0.14 0.02 - 0.81 82% 
Lead V9 FWA 51.64 26.77 3.72 0.05 >999.99 0.44->999.99 88% 
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Figure 3.1: Fibrillatory Wave Amplitude (FWA) Calculation.  Two-second section 
of ECG lead V1 showing AF.  TQ interval highlighted by the dotted grey box.  Peak to 
peak amplitude measurement of consecutive fibrillatory waves is illustrated by red 
lines.  Mean FWA was calculated for consecutive 10-second sections and averaged over 
the 2-minute recording for each ECG lead.  ms = milliseconds; mV = millivolts. 
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 Figure 3.2: ROC Curve – Acute Outcome Risk Score.  Green cross indicates optimal 
cutoff point for sensitivity and specificity.  AUC = area under curve; CI = confidence 
interval; NPV = negative predictive value; PPV = positive predictive value; SE = 
standard error. 
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Figure 3.3: ROC Curve – 12-month Outcome Risk Scores.  Red line indicates 
multivariate risk score from baseline surface AF and clinical parameter analysis.  Blue 
line indicates multivariate risk score from baseline surface AF and clinical parameters 
in combination with the change in surface AF parameters after ablation.  Green cross 
indicates optimal cutoff point for sensitivity and specificity.  Abbreviations as for 
Figure 3.2  
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Chapter 4.  Effect of catheter ablation on quality of life in patients with 
atrial fibrillation and its correlation with arrhythmia outcome 
4.1 Abstract 
Objective 
To assess the effect of catheter ablation on AF symptoms and quality of life (QoL). 
Methods 
Patients with AF scheduled for ablation were recruited.  Pulmonary vein isolation (PVI) 
was performed and CFAE ± linear ablation undertaken in patients in AF despite PVI.  
QoL and AF symptoms were assessed using SF-36 V2 and AFEQT questionnaires 
before and 3-months after ablation.  Change in QoL scores after ablation was correlated 
with clinical parameters and the extent of ablation.  Magnitude of QoL change was 
compared between AFEQT and SF-36 physical (PCS) and mental (MCS) component 
scores and correlated with arrhythmia outcome.    
Results 
80 patients were studied.  Summative and individual health scores for both AFEQT 
(51.5 ± 22.0 vs. 81.3 ± 18.2; p<0.01) and SF-36 (PCS 43.3 ± 10.5 vs. 47.9 ± 11.3; 
p<0.01 and MCS 45.0 ± 11.5 vs. 51.5 ± 9.4; p<0.01) improved significantly in patients 
who maintained sinus rhythm after ablation, but not in those with recurrent AF.  
Improvement in AFEQT (25.4 ± 19) was significantly greater than change in PCS (6.8 
± 6.4; p<0.01) and MCS (8.5 ± 7.9; p<0.01) scores and correlated more closely with 
arrhythmia outcome (AFEQT r=0.55; PCS r=0.26; MCS r=0.30). 
Conclusions 
Patients who maintained sinus rhythm after ablation had a significant improvement in 
AF symptoms and QoL; however, no improvement was observed in patients with 
recurrent AF.  QoL change after ablation did not correlate with baseline clinical 
parameters or ablation strategy.  AF specific QoL scales are more responsive to change 
and correlate better with ablation outcome. 
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4.2 Introduction 
Atrial fibrillation is the most common arrhythmia in clinical practice affecting up to 2% 
of the general population and is associated with significant morbidity and mortality 
(Camm et al., 2010).  Although some patients with AF are asymptomatic, the majority 
seek treatment to improve symptoms and quality of life (QoL), which is reduced 
compared to the general population (Dorian et al., 2000; Hagens et al., 2004; 
Purerfellner et al., 2004).  Treatment strategies including antiarrhythmic drugs (Dorian 
et al., 2002), ventricular rate control (Levy et al., 2001) and catheter ablation (Reynolds 
et al., 2010) improve QoL particularly if sinus rhythm can be restored and maintained 
(Singh et al., 2006).  However, several studies have reported an improvement in QoL 
after ablation irrespective of procedural outcome (Wokhlu et al., 2010b; Fichtner et al., 
2012; Mantovan et al., 2013).  The most widely validated generic QoL scale is the 
Medical Outcomes Study Short Form Health Survey (SF-36), which has been 
successfully used to study a range of cardiovascular conditions including AF (Gronefeld 
et al., 2003).  The greatest weakness of generic QoL measures is that, by design, they 
reflect general health and functioning, and therefore, results are strongly influenced by 
patient demographics and comorbidity.  Therefore, Spertus et al. (2011) developed the 
Atrial Fibrillation Effect on Quality-of-Life (AFEQT) questionnaire as a disease-
specific measure to evaluate QoL in AF patients.  The aim of this study was to assess 
the effect of catheter ablation on AF symptoms and QoL in patients with paroxysmal or 
persistent AF using the AFEQT and SF-36 Version 2 questionnaires. 
4.3 Methods 
4.3.1 Patient Recruitment 
Study participants were recruited from patients scheduled to undergo their first catheter 
ablation procedure for symptomatic AF.  In line with usual practice, class I and III 
antiarrhythmic drugs were discontinued five half-lives prior to ablation. 
4.3.2 Ethical Approval 
This study complies with the Declaration of Helsinki and was granted a favourable 
ethical opinion by the National Research Ethics North West Committee (REC reference: 
11/NW/0476).  Written informed consent was obtained from all patients recruited to the 
study. 
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4.3.3 Quality of Life and AF Symptom Assessment 
QoL and AF symptoms were assessed at baseline and three months after ablation using 
SF-36 V2 and AFEQT questionnaires (Appendix 2).  Questionnaires were completed 
without input from study personnel.  SF-36 V2 consists of 36 items that assess eight 
health domains: physical functioning (PF), role limitations because of physical 
problems (RP), bodily pain (BP), general health perception (GH), vitality (VT), social 
functioning (SF), role limitations because of emotional problems (RE) and mental 
health (MH).  In addition to these eight subscales, physical (PCS) and mental 
component summary (MCS) scores are also generated, which are normalised to an 
overall population mean of 50 ± 10 (Gronefeld et al., 2003).  For all subscales, higher 
scores represent better functioning and QoL.  AFEQT is a 20-item questionnaire that 
assesses four health domains: symptoms (n=4), daily activities (n=8), treatment concern 
(n=6) and satisfaction (n=2) (Spertus et al., 2011).  It combines symptoms, functional 
status and QoL in a single measure and its results have been shown to be reproducible 
and responsive to change (Spertus et al., 2011).  Patients’ responses are scored using a 
seven-point Likert scoring system and a linear relationship is observed between global 
AFEQT scores and AF severity, with the most severely affected patients having the 
lowest scores. 
4.3.4 Ablation Protocol 
The ablation protocol (PVI ± linear ± CFAE ablation) is described in Chapter 3 (Section 
3.3.2). 
4.3.5 Clinical Outcome 
Clinical outcome was determined by symptom review, 12-lead ECG and 72-hour Holter 
monitoring three months after ablation and was divided into two categories: (1) Sinus 
rhythm (no arrhythmia symptoms and no documented AF episodes >30 seconds); (2) 
AF recurrence (documented AF episodes >30 seconds). 
4.3.6 Statistical Analyses 
Continuous variables are expressed as mean ± SD.  Patient characteristics were 
compared between paroxysmal and persistent AF groups using Student’s independent t-
test for continuous variables and Pearson’s chi-squared test for categorical variables.  
Baseline QoL scores (AFEQT, PCS and MCS) were compared and correlated with 
clinical parameters using Pearson’s correlation.  Individual and summative health 
domains of the AFEQT and SF-36 V2 questionnaires were compared at baseline and 
three months after ablation using Student’s paired t-tests.   
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Change in QoL scores after ablation were correlated with clinical parameters using 
Pearson’s correlation (continuous variables) and independent t-test (categorical 
variables) and were compared between different ablation strategies using one-way 
ANOVA.  Parameters with p<0.05 were entered into a multivariate linear regression 
model using stepwise selection to assess their independent and combined ability to 
predict change in QoL after ablation.  After multivariate analysis, parameters with 
p<0.10 were retained.  Standardised coefficients (beta) and corresponding p values are 
reported.  The magnitude of QoL change after ablation was compared between AFEQT, 
PCS and MCS scores using one-way ANOVA and correlation coefficients for the three 
QoL scores and ablation outcome were compared using Fisher r-to-z transformation.  
All tests were 2-tailed and p<0.05 was considered statistically significant.  
4.4 Results 
The clinical characteristics of the 80 consecutive patients recruited to the study are 
shown in Table 4.1.  The mean age was 57 ± 10 years and 73% were male.  The mean 
duration of AF history was 4 ± 3 years.  Patients with persistent AF (n=36) had a 
significantly shorter AF history, larger left atrial volume and lower left ventricular 
ejection fraction than those with paroxysmal AF (n=44).  54/80 (68%) patients (77% 
paroxysmal; 56% persistent AF) maintained sinus rhythm three months after ablation. 
4.4.1 Effect of Ablation on Quality of Life 
There was a significant increase in the summative and individual health domain scores 
for both AFEQT (51.5 ± 22.0 vs. 81.3 ± 18.2; p<0.01) and SF-36 V2 (PCS 43.3 ± 10.5 
vs. 47.9 ± 11.3; p<0.01 and MCS 45.0 ± 11.5 vs. 51.5 ± 9.4; p<0.01) questionnaires in 
patients who maintained sinus rhythm three months after ablation (Figure 4.1A & 
4.2A).  However, there was no significant change in either summative or individual 
scores from either questionnaire in patients with recurrent AF (Figure 4.1B & 4.2B).  
The magnitude of change in AFEQT score (25.4 ± 19) after ablation was significantly 
greater than the change in PCS (6.8 ± 6.4; p<0.01) or MCS (8.5 ± 7.9; p<0.01) scores 
and there was no significant difference observed between PCS and MCS scores 
(p=0.14).  Change in AFEQT score after ablation correlated more closely with three-
month outcome (r=0.55) than PCS (r=0.26; p=0.03) or MCS (r=0.30; p=0.05) scores.  
In univariate analysis, there was no significant correlation between clinical parameters 
and change in QoL scores after ablation (Table 4.2).   
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Of note, there was no difference in the magnitude of change in QoL after ablation 
between paroxysmal and persistent AF groups (AFEQT 24.3 ± 24.3 vs. 16.3 ± 23.4, 
p=0.14; PCS 3.0 ± 9.2 vs. 3.1 ± 8.7, p=0.98; MCS 5.8 ± 11.2 vs. 2.6 ± 10.1, p=0.19).  
However, higher QoL scores at baseline and AF recurrence correlated with smaller 
changes in QoL scores after ablation for both questionnaires.  In multivariate analysis, 
higher AFEQT, PCS and MCS scores pre ablation and AF recurrence were independent 
predictors of a smaller change in their respective QoL scores after ablation (Table 4.3). 
4.4.2 Change in Quality of Life according to Ablation Strategy 
AFEQT scores increased significantly after PVI, PVI + Linear and PVI + Linear + 
CFAE ablation indicating an improvement in QoL (Table 4.4).  AFEQT scores also 
increased after PVI + CFAE ablation although this did not meet statistical significance 
(p=0.12).  There was a significant increase in PCS and MCS scores after PVI and an 
increase in MCS score after PVI + Linear ablation.  However, there was no significant 
change in PCS and MCS scores after the other ablation strategies.  In addition, there 
was no significant difference in the magnitude of change in QoL scores between the 
four ablation strategies (AFEQT p=0.67; PCS p= 0.49; MCS p= 0.29). 
4.4.3 Relationship between Clinical Variables and Quality of Life 
Baseline AFEQT scores correlated closely with PCS scores (r=0.64, p<0.01) and 
moderately with MCS scores (r=0.43, p<0.01).  However, there was no correlation 
between PCS and MCS scores (r=0.16, p=0.15).  Hypertension was associated with a 
lower baseline AFEQT score and a trend towards a lower MCS score (Table 4.5).  Older 
age and persistent AF were associated with a lower PCS score.  Diabetes was associated 
with a lower MCS score and a trend towards a lower PCS score.  Larger left atrial 
volume was associated with a higher MCS score, which is unlikely to be clinically 
meaningful. 
4.5 Discussion 
4.5.1 Effect of Ablation on Quality of Life 
The main finding of this prospective study is the significant improvement in AF 
symptoms and QoL in patients who maintained sinus rhythm three months after ablation 
and the contrasting lack of improvement in patients with recurrent AF.  This finding 
was consistent across all individual and summative components of the AFEQT and SF-
36 V2 questionnaires.  The mean increase in AFEQT score of 30 points in patients who 
maintained sinus rhythm is consistent with a marked improvement in QoL (Dorian et 
al., 2013).   
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The expected lack of QoL improvement in patients with recurrent AF after ablation is 
clinically coherent and supported by Fiala et al. (2014) and Mohanty et al. (2014).  
However, other groups have reported significant QoL improvements regardless of 
arrhythmia outcome.  In respective studies of 323 and 100 patients who underwent 
ablation for symptomatic AF, Wokhlu et al. (2010b) and Mantovan et al. (2013) 
observed an improvement in QoL in all patients irrespective of ablation outcome.  
Patients who maintained sinus rhythm following ablation had a greater improvement in 
generic QoL scores compared to those with recurrent AF; however, this did not reach 
statistical significance.  Wokhlu et al. (2010b) also assessed the impact of ablation on 
AF symptoms using the Mayo AF Symptom Inventory (Wokhlu et al., 2008) and 
observed a significant reduction in symptoms following ablation in patients who 
maintained sinus rhythm compared to those with recurrent AF.  Fichtner et al. (2012) 
reported similar findings in their study of 133 patients (87 paroxysmal) who underwent 
ablation for symptomatic AF.  Improvements in QoL were observed in all patients three 
months after ablation regardless of AF type and ablation success.  In addition, the 
improvement in QoL was sustained over a 4-year follow up period.  Patients who 
maintained sinus rhythm had a significantly greater improvement in both generic QoL 
scores and AF symptoms compared to those with recurrent AF; however, in contrast to 
Wokhlu et al. (2010b), this was statistically significant in both generic and AF-specific 
assessments.  Improvement in QoL irrespective of ablation outcome might be explained 
by a treatment expectancy effect after ablation, transition from symptomatic to 
asymptomatic AF, reduction in AF burden short of abolition and the limited sensitivity 
of generic QoL measurement scales (e.g. SF36 V2) in measuring outcome following a 
disease specific intervention. 
Previous studies have shown that AF specific QoL scales are more responsive to QoL 
change in this population and correlate better with ablation outcome (Wokhlu et al., 
2010b; Spertus et al., 2011).  This is corroborated by the greater change in QoL score 
after ablation and the stronger correlation with ablation outcome observed with the 
AFEQT questionnaire in this study.  There was no significant correlation between the 
clinical parameters examined (including AF type) and change in QoL scores after 
ablation, as shown by others (Wokhlu et al., 2010b; Fichtner et al., 2012; Mantovan et 
al., 2013).  However, Bulkova et al. (2014) reported that longstanding persistent AF, 
younger age and a shorter history of AF were associated with an improvement in QoL 
three years after ablation.  The different patient populations and longer duration of 
follow up could explain the discordance in results.   
 65 
In agreement with others, higher QoL scores pre ablation and AF recurrence were 
independent predictors of a smaller change in the respective QoL score after ablation 
(Wokhlu et al., 2010b; Mantovan et al., 2013; Dorian et al., 2013).  This suggests a 
ceiling effect, as there is less potential for improvement after ablation in those with 
preserved QoL beforehand. 
4.5.2 Change in Quality of Life according to Ablation Strategy 
Mantovan et al. (2013) reported a significant improvement in PCS and MCS scores 
after PVI, CFAE and PVI + CFAE ablation strategies with the exception of MCS in the 
CFAE ablation group.  In our study, we observed a significant increase in all three QoL 
scores after PVI; however, there was no significant improvement in PCS and MCS 
scores after PVI + CFAE ablation.  This is likely a chance effect on account of the small 
number of patients in this subgroup.  To our knowledge, the effect of PVI + Linear 
ablation on QoL has not been previously reported.  In this study, PVI + Linear ablation 
was associated with a significant improvement in AFEQT and MCS scores; however, 
there was no significant difference in PCS scores.  Of note, there was no significant 
difference in the magnitude of QoL change after ablation between the four ablation 
strategies. 
4.5.3 Relationship between Clinical Variables and Quality of Life 
This study showed no correlation between gender and QoL, in contrast to Reynolds et 
al. (2006) who reported that female patients were more symptomatic from AF with an 
associated reduction in QoL.  In addition, they reported that older patients (>65 years) 
had fewer AF symptoms than their younger counterparts, which was not observed in 
this study.  The disparity in results may be explained by different patient populations 
and eras of AF management as they studied patients with new-onset AF who were 
managed pharmacologically prior to the development of AF ablation; whereas, we 
studied patients referred for ablation who, by their very nature, have a high AF 
symptom burden and reduced QoL.  Hypertension was associated with a higher 
symptom burden and reduced QoL secondary to AF in this study, which has not been 
previously reported.  Persistent AF was associated with lower physical health scores 
than paroxysmal AF, as shown by Bulkova et al. (2014).  However there was no 
difference in AF symptom burden between the two groups, which contradicts the 
common belief that symptoms regress as AF progresses from paroxysmal to persistent 
forms.  Finally, diabetes was associated with lower mental health and a trend towards 
lower physical health scores in this study, which supports its negative impact on quality 
of life. 
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4.6 Limitations 
Firstly, the choice of ablation strategy after PVI was not randomised and was dependent 
on the operator and the degree of signal complexity in the left atrium.  Secondly, this 
was a prospective cohort study without a randomised control group comparing AF 
ablation to best non-ablative management (rate vs. rhythm control).  However, the 
superiority of ablation over antiarrhythmic drugs in improving QoL has been 
demonstrated consistently.  Thirdly, AF recurrence was determined by patients’ 
symptoms, 12-lead ECG and 72-hour Holter monitoring three months after ablation and 
not by continuous ECG monitoring.  Although, we cannot completely exclude 
asymptomatic AF episodes in the ‘sinus rhythm’ group, we consider this unlikely given 
previous AF symptoms.  Fourthly, change in QoL was assessed 3 months after ablation 
in line with the first outpatient clinic review and therefore, the longer-term effect of 
ablation on QoL is unknown.  Finally, patients enrolled in this study had been referred 
for catheter ablation and therefore, represent a select cohort with a high AF symptom 
burden.  Extrapolation of the benefits demonstrated to a wider population requires 
caution. 
4.7 Conclusions 
Patients who maintained sinus rhythm after ablation had a significant improvement in 
AF symptoms and QoL.  No improvement was observed in patients with recurrent AF.  
QoL did not correlate with either baseline clinical parameters or extent of ablation.  AF 
specific QoL scales are more responsive to change than generic measures and correlate 
better with arrhythmia outcome.  
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Table 4.1: Patient Characteristics 
  
 Paroxysmal AF (n=44) Persistent AF (n=36) P Value 
Age (years) 56.9 ± 10.5 58.2 ± 9.5 0.58 
Male Gender 30 (68%) 28 (78%) 0.45 
AF History (years) 4.4 ± 3.4 2.9 ± 2.7 0.04 
LA Volume (ml) 53 ± 17 65 ± 20 <0.01 
LVEF (%) 54 ± 2 51 ± 8 0.02 
Hypertension 12 (27%) 14 (39%) 0.34 
Diabetes 2 (5%) 5 (14%) 0.23 
Smoking 22 (50%) 17 (47%) 0.83 
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Table 4.2: Change in QoL Scores after Ablation: Relationship with Clinical Parameters and Ablation Outcome 
* R values from Pearson’s correlation (continuous variables) and T values from independent t-tests (categorical variables) are shown 
 AFEQT 
R/T (P) 
PCS 
R/T (P) 
MCS 
R/T (P) 
Age -0.02 (0.87) 0.05 (0.70) -0.16 (0.15) 
Female Gender 0.28 (0.78) -1.14 (0.26) 1.31 (0.19) 
Persistent AF 1.48 (0.14) -0.03 (0.98) 1.33 (0.19) 
AF History -0.09 (0.44) -0.18 (0.11) -0.01 (0.96) 
LA Volume <-0.01 (0.98) 0.06 (0.63) -0.34 (<0.01) 
LVEF 0.06 (0.61) -0.05 (0.68) 0.10 (0.38) 
Hypertension -0.57 (0.57) -0.01 (0.99) -0.49 (0.63) 
Diabetes 1.31 (0.20) 0.95 (0.34) -0.23 (0.82) 
Smoking -1.96 (0.05) -0.40 (0.69) -0.67 (0.51) 
Baseline 
AFEQT -0.47 (<0.01) -0.10 (0.37) -0.13 (0.25) 
PCS -0.22 (0.05) -0.34 (<0.01) 0.20 (0.08) 
MCS -0.12 (0.30) 0.16 (0.17) -0.54 (<0.01) 
Three Month Outcome -5.79 (<0.01) -2.39 (0.02) -2.72 (<0.01) 
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Table 4.3: Multivariate Predictors of Change in QoL Scores after Ablation 
 
 
 
 
 
 Parameter Standardised 
Coefficient 
(Βeta) 
P Value 
AFEQT AF Recurrence 0.57 <0.01 
Baseline AFEQT -0.56 <0.01 
PCS Baseline PCS -0.40 <0.01 
Baseline MCS 0.25 0.02 
AF Recurrence 0.23 0.03 
MCS Baseline MCS -0.68 <0.01 
AF Recurrence 0.28 <0.01 
Baseline PCS 0.27 <0.01 
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Table 4.4: Change in QoL Scores according to Ablation Strategy 
 
 
 
 
 
 
 
 
 
 
 AFEQT PCS MCS 
Baseline 3 months P Baseline 3 months P Baseline 3 months P 
PVI (n=45) 53.4 ± 22.3 76.7 ± 20.9 <0.01 43.8 ± 10.7 47.0 ± 11.0 0.02 44.3 ± 12.1 49.8 ± 9.1 <0.01 
PVI + Linear (n=17) 47.6 ± 23.0 62.7 ± 25.5 0.04 44.5 ± 98 44.9 ± 10.4 0.82 45.4 ± 10.5 50.9 ± 9.4 0.04 
PVI + CFAE (n=8) 39.2 ± 15.3 56.9 ± 22.3 0.12 38.2 ± 12.5 43.2 ± 11.7 0.26 44.1 ± 13.8 47.0 ± 11.6 0.46 
PVI + Linear + CFAE (n=10) 52.1 ± 23.2 72.5 ± 29.0 0.02 43.0 ± 13.0 48.2 ± 15.8 0.14 49.5 ± 8.3 48.0 ± 14.1 0.65 
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Table 4.5: Baseline QoL Scores and Clinical Parameters 
* R values from Pearson’s correlation (continuous variables) and T values from independent t-tests (categorical variables) are shown
 AFEQT 
R/T (P) 
PCS 
R/T (P) 
MCS 
R/T (P) 
Age -0.14 (0.22) -0.35 (<0.01) 0.05 (0.69) 
Female Gender 1.01 (0.31) 1.13 (0.26) -0.14 (0.89) 
Persistent AF 1.64 (0.10) 2.05 (0.04) 0 (1) 
AF History 0.14 (0.22) 0.20 (0.09) -0.04 (0.76) 
LA Volume -0.03 (0.82) -0.20 (0.09) 0.33 (<0.01) 
LVEF -0.01 (0.96) 0.12 (0.29) -0.08 (0.47) 
Hypertension 2.22 (0.03) 1.43 (0.16) 1.93 (0.06) 
Diabetes 1.38 (0.17) 1.81 (0.07) 2.64 (0.01) 
Smoking 1.21 (0.23) 0.35 (0.73) 0.96 (0.34) 
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Figure 4.1: Mean individual and summative AFEQT scores before and three 
months after ablation.  Figure 4.1A = patients who maintained sinus rhythm post 
ablation; Figure 4.1B = patients with recurrent AF.  AFEQT = overall AFEQT score; 
DA = daily activities; SY = symptoms; TC = treatment concern; TS = treatment 
satisfaction. 
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 Figure 4.2: Mean individual and summative SF-36 V2 scores before and three 
months after ablation.  Figure 4.2A = patients who maintained sinus rhythm post 
ablation; Figure 4.2B = patients with recurrent AF.  PCS = physical component 
summary; MCS = mental component summary; PF = physical functioning, RP = role 
limitations because of physical problems, BP = bodily pain, GH = general health 
perception, VT = vitality, SF = social functioning, RE = role limitations because of 
emotional problems; MH = mental health. 
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Chapter 5.  Inter-atrial frequency gradients and dominant frequency 
variability in patients with persistent atrial fibrillation: Insights from 
multipolar contact mapping 
5.1 Abstract 
Introduction 
In an observational study, the majority of patients with persistent AF had a ‘right-to-
left’ atrial frequency gradient with a significantly higher dominant frequency (DF) in 
the right atrium compared to the coronary sinus and pulmonary veins.  The aim of this 
study was to investigate inter-atrial frequency gradients and DF variability in patients 
with persistent AF using a basket catheter to collect data simultaneously from multiple 
atrial sites. 
Methods and Results 
Twelve patients were studied.  The basket catheter was deployed sequentially in the 
right and left atrium and 1-minute recordings were collected from one/two positions in 
each chamber.  Separate recordings were collected from the coronary sinus and 
pulmonary veins.  Mean DF was calculated for each bipole using Fourier analysis. 
Five patients had a ‘left-to-right’ (LA 7.3 ± 0.7Hz vs. RA 6.7 ± 0.7Hz; p<0.001) and 
three patients had a ‘right-to-left’ atrial frequency gradient (RA 6.9 ± 1.2Hz vs. LA 6.2 
± 0.9Hz; p<0.001).  The location of DFMAX (highest frequency site) remained stable 
throughout the 1-minute recording in all patients.  Mean temporal coefficient of 
variation for DF in the whole group was 4.5 ± 2.1% and was significantly higher in the 
right compared to the left atrium (4.9 ± 2.1% vs. 4.4 ± 2.1%; p<0.001). 
Conclusions 
A proportion of patients with persistent AF have a ‘right-to-left’ atrial frequency 
gradient implying that their arrhythmia is maintained by high frequency sources in the 
right atrium.  These sources are anatomically stable over a 1-minute period.  The 
effectiveness of ablating these sites warrants further investigation. 
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5.2 Introduction 
A left-to-right atrial frequency gradient during AF was first described by Mansour et al. 
(2001) using high-resolution optical and electrode-based mapping of isolated sheep 
hearts.  AF was induced using a combination of burst pacing and increasing 
concentrations of acetylcholine and dominant frequency (DF) maps were created using 
fast Fourier transform (FFT) algorithms.  They reported that left atrial DF was 
consistently higher than in the right atrium and hypothesised that high-frequency 
sources in the left atrium were responsible for maintaining AF (Mansour et al., 2001).  
Lazar et al. (2004) corroborated these findings by demonstrating a left-to-right atrial 
frequency gradient in patients with paroxysmal AF.  They also found that patients with 
left-to-right atrial frequency gradients had better clinical outcomes following pulmonary 
vein isolation but that the majority of patients with persistent AF did not have an inter-
atrial frequency gradient (Lazar et al., 2004 and 2006).  Interestingly, none of their AF 
patients had a right-to-left atrial frequency gradient, which is at odds with our own 
experience.  In an observational study of 41 patients with persistent AF (Raine et al., 
2013), we observed a right-to left atrial frequency gradient in 63% of patients with a 
significantly higher DF recorded in the high right atrium compared to the coronary sinus 
and pulmonary vein ostia prior to ablation (Table 5.1).  The remaining patients had a 
left-to-right atrial frequency gradient with a significantly higher DF in the pulmonary 
vein ostia compared to the coronary sinus and high right atrium (Table 5.1).  The 
presence of a right-to-left atrial frequency gradient implies that the arrhythmia is being 
maintained by high frequency sources in the right atrium.  This has profound 
implications for ablation strategies since currently the right atrium is largely ignored 
and considered a bystander chamber not critical to the maintenance of AF.  The obvious 
limitation of the observational study was the small number of atrial sites sampled 
simultaneously for electrogram analysis.  Therefore, the aim of this study was to 
investigate inter-atrial frequency gradients and temporal and spatial variability of DF in 
patients with persistent AF using a 64-electrode contact mapping catheter 
(Constellation®, Boston Scientific) to record simultaneous electrograms from multiple 
sites in the left and right atria.   
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5.3 Methods 
5.3.1 Patient Recruitment 
Study participants were recruited from patients with persistent AF (AF episode duration 
>7 days (Camm et al., 2010)) undergoing their first catheter ablation procedure for 
standard clinical indications.  Class I and III antiarrhythmic drugs were discontinued 
five half-lives prior to ablation.  Patients were excluded from the study if they were 
unable to give written informed consent or were taking amiodarone – because of its 
long half-life and effects on cardiac electrophysiology.  Transverse and longitudinal 
right and left atrial measurements were obtained from apical two and four-chamber 
views on transthoracic echocardiography two weeks prior to the ablation procedure to 
enable appropriate sizing of the Constellation® catheter. 
5.3.2 Ethical Approval 
This study complies with the Declaration of Helsinki and was granted a favourable 
ethical opinion by the West of Scotland Research Ethics Committee (REC reference: 
13/WS/0141).  Written informed consent was obtained from all patients included in the 
study. 
5.3.3 Study Protocol 
At the start of the ablation procedure, electroanatomical maps of both atria were created 
using a bipolar irrigated-tip ablation catheter and the EnSite Velocity™ cardiac 
mapping system (St. Jude Medical).  A Constellation® catheter was then deployed 
sequentially in the right and left atrium (Figure 5.1) and one-minute intracardiac 
recordings were collected from one or two catheter positions in each atrium to ensure 
satisfactory coverage of the chamber.  If satisfactory contact with all areas of the atria 
could not be achieved using Constellation®, a bipolar ablation catheter was used to 
collect sequential 1-minute recordings from these inadequately covered sites to 
complete high-resolution DF maps of both atria.  Intracardiac recordings were also 
collected simultaneously from the coronary sinus (CS) (steerable decapolar catheter) 
and sequentially from each of the pulmonary vein ostia (ablation catheter).  The distal 
poles of the CS catheter were positioned on the lateral aspect of the mitral valve ring, 
with proximal bipole CS9-10 just inside the ostium of the coronary sinus.   
5.3.4 Intracardiac Data Analysis 
All intracardiac signals were filtered using a standard bandpass of 30-250Hz and 
recorded on a Labsystem Pro™ recording system (Bard EP) at a digital sampling rate of 
1000Hz for offline analysis in Matlab® 2013.   
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To preserve signal integrity, no additional filtering was applied.  The 64 electrodes on 
the Constellation® catheter were employed in an overlapping format to record 56 bipolar 
electrograms.  Power spectral density (PSD) of consecutive 10-second sections of 
bipolar electrograms was estimated by periodogram with rectangular window and 
frequency resolution of 0.1Hz.  For each section, DF was identified as the intracardiac 
frequency with the highest power in the range 3-10Hz as previously defined (Raine et 
al., 2004 and 2005).  DFs were verified to be in close agreement with the number of 
electrogram activations per second by plotting the electrograms and corresponding 
PSDs as illustrated in Figure 5.2.  Mean and SD values of DF from the one-minute 
recordings are reported. 
5.3.5 Statistical Analyses 
Continuous variables are expressed as mean ± SD.  Mean DF from each atrium were 
compared using Student’s independent t-tests to identify significant inter-atrial 
frequency gradients.  DFMEAN from different atrial and CS sites were compared to 
DFMAX in the corresponding atrium or coronary sinus using a one-sample t-test and 
correction for multiple comparisons was performed using the sequential Bonferroni 
method.  Temporal and spatial variability of DF were quantified using the coefficient of 
variation, which is a normalised measure defined as the ratio of the SD to the mean.  
Temporal coefficients of variation were compared between different atrial sites and 
between patients using a one-way ANOVA. Spatial coefficients of variation were 
compared between left and right atria using a paired t-test.  All tests were 2-tailed and 
p<0.05 was considered statistically significant. 
5.4 Results 
Characteristics of the 12 consecutive patients recruited to the study are shown in Table 
5.2.  Ten of the 12 patients had longstanding persistent AF (AF episode duration ≥1 
year (Camm et al., 2010)).  60mm Constellation® catheters (5mm inter-electrode 
spacing) were used in eight patients and 48mm catheters (4mm inter-electrode spacing) 
in the remaining four patients based on their atrial dimensions on transthoracic 
echocardiography.  All patients required two Constellation® catheter positions in the left 
atrium and 7/12 patients required two catheter positions in the right atrium.  The number 
of Constellation® catheter bipoles with electrograms suitable for FFT analysis (i.e. 
containing atrial activity without significant artefact or noise) was 2034/2688 (76%) – 
RA 1179/1344 (88%) vs. LA 855/1344 (64%). 
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5.4.1 Inter-Atrial Frequency Gradients 
Five patients (42%) had a ‘left-to-right’ atrial frequency gradient (LA DFMEAN 7.3 ± 
0.7Hz vs. RA DFMEAN 6.7 ± 0.7Hz; p<0.001) (Figure 5.3).  In these, DFMAX was 
located in the lateral left atrium (n=2), roof (n=1), left lower pulmonary vein (n=1) or 
distal CS (n=1).  Three patients (25%) had a ‘right-to-left’ atrial frequency gradient (RA 
DFMEAN 6.9 ± 1.2Hz vs. LA DFMEAN 6.2 ± 0.9Hz; p<0.001) with DFMAX located at 
superior vena cava (SVC) / RA junction (n=1), right atrial appendage (RAA) ostium 
(n=1) or posterior right atrium (n=1).  The remaining four patients (33%) had no 
significant inter-atrial frequency gradient (LA DFMEAN 6.4 ± 0.4Hz vs. RA DFMEAN 6.5 
± 0.5Hz; p=0.22).  Inter-atrial frequency gradients and the location of DFMAX remained 
stable throughout the 1-minute recordings in all patients (temporal coefficient of 
variation 4.1 ± 0.8%).  In addition, the site with the second highest DF was located in 
the same atrium as DFMAX in all patients.   
5.4.2 Dominant Frequency Distribution 
The distribution of dominant frequencies according to intracardiac site is shown in 
Table 5.3.  In the right atrium, the RAA ostium had a significantly higher DF (7.0 ± 
1.0Hz) compared to the floor (6.5 ± 0.6Hz; p<0.001) and septum (6.6 ± 0.8Hz; 
p<0.001).  In the left atrium, the lateral wall (6.9 ± 1.0Hz), left atrial appendage (LAA) 
ostium (6.9 ± 1.0Hz) and roof (6.9 ± 0.9Hz) had significantly higher DF compared to 
the floor (6.6 ± 0.7Hz; p<0.001).  In the coronary sinus, the highest DF was found in the 
distal electrode pair CS3-4 (6.7 ± 1.1Hz); however, this was not significantly higher than 
the other electrode pairs.   
5.4.3 Temporal and Spatial Variability of DF 
The mean temporal coefficient of variation for DF in the whole group was 4.5 ± 2.1% 
(range 0–12.8%).  Temporal variability of DF was significantly higher in the right 
atrium (4.9 ± 2.1%) compared to the left atrium (4.4 ± 2.1%; p<0.001).  In contrast, 
temporal variability of DF was significantly lower in the CS (3.4 ± 1.4%) compared to 
the right atrium (4.9 ± 2.1%; p<0.001), left atrium (4.4 ± 2.1%; p<0.001) or pulmonary 
veins (4.6 ± 1.6%; p<0.01).  Significant differences in temporal variability of DF in 
both atria were observed between patients (p<0.001) (Figure 5.4) and between different 
intracardiac sites (p<0.001) (Figure 5.5).  The highest temporal variability of DF was 
observed in the right lower pulmonary vein (5.8 ± 1.6%) and right atrial septum (5.7 ± 
3.0%) and the lowest temporal variability of DF observed in the left atrial septum (1.3 ± 
1.1%) and inferior vena cava (1.4 ± 1.7%).   
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The mean spatial coefficient of variation for DF in the whole group was 7.0 ± 2.7% 
(range 3.8–13.7%).  In contrast to temporal variability, there was no significant 
difference in spatial variability of DF between right and left atria (6.2 ± 2.6% vs. 4.7 ± 
1.5%; p=0.14). 
5.5 Discussion 
This study is the first to investigate inter-atrial frequency gradients in patients with 
persistent AF using the simultaneous multipoint recording capability of the 
Constellation® catheter.  To optimise fidelity of recordings, mean DF for each bipolar 
electrogram was calculated over one-minute rather than sequentially over 6.82 seconds 
as used by EnSite Velocity™ for creation of its automated DF maps.  The longer 
recording negated the impact of transient high frequency sites and facilitated the 
creation of high-resolution frequency maps of both atria.  This study is also the first to 
investigate temporal and spatial variability of DF in the right atrium in patients with 
persistent AF, building on the work of Habel et al. (2010) who investigated DF 
variability in the left atrium using multipolar recordings in a cohort of patients with 
paroxysmal or persistent AF.   
5.5.1 Inter-Atrial Frequency Gradients 
Consistent with the results of Lazar et al. (2004 and 2006), five of the 12 patients in this 
study had a left-to-right atrial frequency gradient and four patients had no inter-atrial 
frequency gradient.  However, the remaining three patients (25%) had a right-to-left 
atrial frequency gradient with DFMAX located at the SVC/RA junction, RAA ostium or 
posterior right atrium.  This implies the arrhythmia in these patients is maintained by 
high frequency sources in the right atrium and therefore, they would not be expected to 
maintain sinus rhythm following conventional left atrial ablation procedures.  Our 
results are in agreement with those of Narayan et al. (2012) who reported that 24% of 
patients enrolled in their CONFIRM trial had AF sources (electrical rotors and/or focal 
impulses) located in the right atrium.  The fact that Lazar et al. (2004 and 2006) did not 
find right-to-left atrial frequency gradients in any of their patients may be explained by 
differences in the methods used to collect intracardiac electrograms.  Whereas, they 
recorded electrograms simultaneously from decapolar catheters in the coronary sinus 
and posterior right atrium and a circular mapping catheter in the posterior left atrium, 
we ensured more comprehensive coverage of both atria using a Constellation® catheter 
positioned in one/two locations in each chamber and a decapolar catheter in the 
coronary sinus.   
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Another key finding from this study is that inter-atrial frequency gradients and the 
location of DFMAX remained stable throughout the 1-minute recording in all patients.  
Stability of high frequency sites over a 30-second period in patients with persistent AF 
has been reported recently by Salinet et al. (2014) using non-contact mapping.  Longer-
term stability over a 1-minute recording has not been reported and supports the 
hypothesis that DFMAX sites are important to the maintenance of AF and therefore 
should be targeted with ablation. 
5.5.2 Dominant Frequency Distribution 
In their study of 50 patients with persistent AF, Lin et al. (2010) investigated the spatial 
distribution of DFMAX sites in the left atrium using high-density frequency mapping.  
They reported that DFMAX was most commonly found in the left atrial septum (32%), 
LAA ridge (19%), posterior wall (19%) or pulmonary vein antrum (14%).  In the five 
patients in our study with left-to-right atrial gradients, DFMAX was located in the lateral 
left atrium (n=2), roof (n=1), left lower pulmonary vein (n=1) or distal CS (n=1).  The 
discordance in results may again be explained by differences in the methods of data 
collection.  Lin et al. (2010) created high-density frequency maps of the left atrium 
using the automated DF software in EnSite Velocity™ as previously discussed.  We 
calculated mean DF for each catheter bipole from each 1-minute recording to provide a 
global assessment of atrial frequencies and to negate the impact of transient high-
frequency activity.   
To our knowledge, the distribution of dominant frequencies in both atria has not been 
previously studied using multipolar recordings.  In this study, the highest mean left 
atrial DF was found in the lateral wall and LAA ostium, which were significantly higher 
than the left atrial floor.  In the right atrium, the RAA ostium had a significantly higher 
DF compared to the floor and septum.  The identification of high frequency activity – 
likely contributing to the maintenance of AF – in the atrial appendages is of particular 
interest since these sites have traditionally been unattractive regions for ablation 
because of their complex thin-walled structure, contribution to atrial contractility and 
role in thromboembolism.  However, evidence that electrical isolation of the left atrial 
appendage abolishes its contractile function and exposes the patient to a higher risk of 
thromboembolism is lacking.  In a study of 987 patients (71% persistent AF), Di Biase 
et al. (2010) reported a significant improvement in ablation outcome in patients with 
documented high frequency LAA activity who underwent circumferential LAA 
isolation.   
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In addition, LAA mechanical function was maintained in 53% of these patients and no 
LAA thrombus was observed (including in those with poor LAA contractility).   
5.5.3 Temporal and Spatial Variability of DF 
In this study, the mean temporal and spatial coefficients of variation for DF were 4.5 ± 
2.1% and 7.0 ± 2.7%, which are significantly lower than the 22.7 ± 5.4% and 26.9 ± 
6.6% reported by Habel et al. (2010).  The differing results may be explained by the 
shorter duration of recording (1-minute vs. 5-minute) and longer analysis sections (10-
second vs. 5-second).  Furthermore, we recorded data from additional intracardiac sites 
including the right atrium, CS and pulmonary veins and ensured complete coverage of 
both atria by supplementary recordings using a bipolar ablation catheter in areas of 
inadequate endocardial contact with Constellation®.  Interestingly, temporal variability 
of DF was significantly lower in the left atrium compared to the right atrium.  This 
reflects more organised activity in the left atrium, which in turn could represent rotors 
and/or focal AF drivers responsible for maintaining AF.  Another possible explanation 
for the higher temporal variability of DF in the right atrium is its’ more complex 
anatomical structure.  In agreement with Habel et al. (2010), we observed significant 
differences in temporal variability of DF between patients and between different atrial 
sites (p<0.001).  In the right atrium, the lowest temporal variability of DF was observed 
in the IVC, SVC, crista terminalis and roof.  Conversely in the left atrium, the septum, 
roof, anterior, posterior and lateral walls had the lowest temporal variability of DF.  
High frequency activity in these areas is likely to represent an AF source on account of 
the inherent low temporal variability.  Finally, despite an average 7% variation in DF 
across both atria, there was no significant difference in the degree of spatial variation of 
DF between the left and right atrium. 
5.6 Limitations 
Firstly, the findings need to be interpreted cautiously since only 12 patients were 
studied.  Secondly, only one Constellation® catheter was deployed per patient, which, 
theoretically, meant that the size of catheter could not be optimised to the individual 
dimensions of either atrium.  However, this did not result in a significant compromise in 
this study as all of the patients had similar sized right and left atria.  Thirdly, we 
collected data sequentially from one or two catheter positions in each atrium to ensure 
optimum coverage of the chamber.  This meant a compromise between maximising the 
number of atrial sites recorded and the degree to which all electrograms were recorded 
simultaneously.  In light of the above, we were unable to collect true simultaneous inter- 
and intra-atrial recordings in all patients.   
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This was due primarily to limitations in the ability of the Constellation® catheter to 
provide comprehensive coverage of either atria from one position.  This was most 
apparent in the left atrium where only 64% of the Constellation® catheter bipoles 
contained electrograms suitable for FFT analysis despite being deployed through a 
steerable sheath.  The Constellation® catheter had greatest difficulty in achieving 
endocardial contact with the left atrial floor and septum; therefore, a bipolar ablation 
catheter was needed to record electrograms from these sites when necessary.  
Nevertheless, we were able to record data from the left atrial septum in 9/12 patients 
using Constellation® by flexing the sheath around the left atrium and deploying the 
catheter with its’ tip pointing towards the right upper pulmonary vein.  However, this 
manoeuvre can only be performed in patients with a significantly dilated left atrium.  
Finally, with regard to spectral DF analysis, potential limitations include: (1) 
overestimation of DF due to double counting; (2) impact of far-field ventricular 
depolarisations and noise; (3) significant DF variability with short recording durations 
(Narayan et al., 2006; Ng et al., 2007).  We attempted to address these limitations by 
using bipolar recordings to reduce the impact of far field ventricular depolarisations and 
by ensuring that any potential sources of electrical noise were removed from the 
recording apparatus.  We also used a frequency range of 3-10Hz to extract the atrial DF 
and calculated mean DF from consecutive 10-second sections across the 1-minute 
recording to negate the impact of transient high frequency activity.  In addition, we 
plotted the electrograms and corresponding PSDs to verify that the calculated DF was in 
close agreement with AF cycle length. 
5.7 Conclusions 
High-density frequency analysis of both atria showed that 25% of the patients with 
persistent AF studied had a ‘right-to-left’ atrial frequency gradient.  This implies that 
their arrhythmia is maintained by high frequency sources in the right atrium.  These 
sources were anatomically stable over a one-minute period and typically exhibited 
organised activity with low temporal variability.  The effectiveness of targeting these 
sites with ablation warrants further investigation.
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Table 5.1: Inter-Atrial Frequency Gradients.  The proportion of patients with right-
to-left and left-to-right atrial frequency gradients from the observational study (Raine et 
al., 2013) is shown.  Respective intracardiac dominant frequencies from the high right 
atrium, coronary sinus and highest frequency pulmonary vein and the P values from the 
inter-site comparisons are quoted. 
  
Atrial Frequency 
Gradient 
Mean ± SD Intracardiac Dominant Frequency (Hz) 
High Right Atrium Coronary Sinus Pulmonary Vein with highest DF 
Right-to-Left 
(n=26; 63%) 6.89 ± 0.82 
6.08 ± 0.71 
(p<0.001) 
6.37 ± 0.55 
(p<0.001) 
Left-to-Right 
(n=15; 37%) 
6.45 ± 1.10 
(p=0.013) 
6.23 ± 1.07  
(p=0.005) 7.11 ± 0.86 
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Table 5.2: Patient Characteristics 
  
Age (years) 56 ± 8 
Male Gender 10 (83%) 
AF Duration (months) 21 ± 11 
LA Volume (ml) 119 ± 37 
RA Volume (ml) 128 ± 59 
LVEF (%) 52 ± 5 
Hypertension 6 (50%) 
Diabetes 1 (8%) 
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Table 5.3: Mean Dominant Frequencies (Hz) by Intracardiac Site 
* P value from one-sample t-test comparing DFMEAN at each site with DFMAX in the 
corresponding atrium or coronary sinus.  P values highlighted in bold remain significant 
after correcting for multiple comparisons using sequential Bonferroni method. 
  
 Intracardiac Site DFMEAN (Hz) 
P Value* 
Right Atrium 
(DFMAX 7.0Hz) 
 
RAA 7.0 ± 1.0 N/A 
SVC 6.9 ± 0.9 0.68 
Crista Terminalis 6.9 ± 0.9 0.45 
Roof 6.8 ± 0.8 0.17 
Posterior 6.7 ± 0.8 0.04 
Anterior 6.7 ± 0.8 0.02 
IVC 6.6 ± 0.8 0.07 
Septum 6.6 ± 0.8 <0.001 
Floor 6.5 ± 0.6 <0.001 
Left Atrium 
(DFMAX 6.9Hz) 
Lateral 6.9 ± 1.0 N/A 
LAA 6.9 ± 1.0 0.99 
Roof 6.9 ± 0.9 0.94 
LUPV 6.8 ± 0.6 0.64 
LLPV 6.8 ± 0.7 0.60 
Posterior 6.8 ± 0.9 0.39 
Anterior 6.7 ± 0.9 0.17 
Floor 6.6 ± 0.7 <0.001 
Septum 6.5 ± 0.8 0.07 
RLPV 6.5 ± 0.6 0.09 
RUPV 6.4 ± 0.7 0.05 
Coronary Sinus 
(DFMAX 6.7Hz) 
CS 3-4 (Distal) 6.7 ± 1.1 N/A 
CS 7-8 6.5 ± 1.1 0.50 
CS 5-6 6.3 ± 1.1 0.37 
CS 9-10 (Proximal) 6.2 ± 1.0 0.17 
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Figure 5.1: Constellation® catheter deployed in the right atrium (top panel) and left 
atrium (bottom panel) with guidance from the EnSite Velocity™ cardiac mapping 
system.  The eight catheter splines are labelled and shown in different colours.  AP = 
anteroposterior; CT = crista terminalis; IVC = inferior vena cava; LAA = left atrial 
appendage; LUPV = left upper pulmonary vein; RAA = right atrial appendage; RLPV = 
right lower pulmonary vein; RUPV = right upper pulmonary vein; SVC = superior vena 
cava.
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 Figure 5.2: Bipolar intracardiac electrograms and dominant frequency spectra.  Each 1-minute recording is divided into six 10-second 
sections and the corresponding frequency spectrum for each 10-second section displayed.  Dominant frequency is highlighted in red.
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Figure 5.3: Bi-atrial dominant frequency map illustrating a left-to-right atrial 
frequency gradient. Each atrium is divided into 32 sectors (16 anterior and 16 
posterior). The highest dominant frequency is highlighted in orange and located in the 
anterolateral left atrium. 
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Figure 5.4: Mean temporal variability of DF in the right atrium (top panel) and left 
atrium (bottom panel) for each patient. The circles indicate the mean value and the 
error bars represent one standard deviation from the mean.
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 Figure 5.5: Temporal variability of DF (%) according to intracardiac site. LAT = lateral wall; SEP = septum. Other abbreviations as for Figure 5.1
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Chapter 6.  Multipolar contact mapping guided ablation of temporally 
stable high frequency and complex fractionated atrial electrogram 
sites in patients with persistent atrial fibrillation 
6.1 Abstract 
Introduction 
Previous studies of high frequency and CFAE site ablation have produced conflicting 
results.  The aims of this study were: (1) To investigate the distribution and 
effectiveness of ablating high frequency (≥8Hz) and highly repetitive CFAE (interval 
confidence level ≥120) sites in patients with persistent atrial fibrillation (AF) using a 
basket catheter to collect data simultaneously from multiple atrial sites; (2) To assess 
the utility of intra-procedural flecainide in identifying critical AF sites. 
Methods and Results 
Twelve patients were studied.  The basket catheter was deployed sequentially in both 
atria and 1-minute recordings collected from one/two positions in each chamber. 
Separate recordings were collected from the coronary sinus and pulmonary veins.  Sites 
that exhibited high frequency and/or fractionated activity throughout the recordings 
were identified.  All patients underwent pulmonary vein isolation and the eleven who 
remained in AF received flecainide.  Further recordings from both atria were collected.  
High frequency and highly repetitive CFAE sites were ablated. 
High frequency sites were found in 4/12 patients: 32 right atrium (RA) and 31 left 
atrium (LA).  Highly repetitive CFAEs were more commonly identified (RA 377; LA 
296).  Flecainide reduced CFAE burden significantly (85% RA; 79% LA).  No patient 
cardioverted to sinus rhythm during high frequency or CFAE ablation.  5/12 (42%) 
patients were free of AF at 12-months. 
Conclusions 
Highly repetitive CFAEs are distributed throughout both atria in persistent AF.  High 
frequency sites (≥8Hz) are less commonly identified.  Flecainide does not help identify 
critical sites.  Twelve-month outcome was similar to that reported after other ablation 
techniques.
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6.2 Introduction 
High-frequency microreentrant sources perpetuating AF were initially described by 
Mandapati et al. (2000) using high-resolution optical mapping in a sheep model.  These 
findings were corroborated in humans by Sanders et al. (2005) using spectral analysis 
and frequency mapping.  They observed that ablation of high frequency sites in both 
atria and the coronary sinus terminated AF in 17/19 patients with paroxysmal AF but 
did not restore sinus rhythm in any patient with persistent AF.  More recent studies on 
the ablation of high frequency sites have produced conflicting results.  Complex 
fractionated atrial electrogram (CFAE) ablation was first proposed by Nademanee et al. 
(2004).  In their study of 121 patients (64 persistent AF), 110 (91%) patients were free 
from AF at 12 months following bi-atrial CFAE ablation.  However, other groups have 
been unable to replicate their findings (Estner et al., 2008b; Oral et al., 2009).  In the 
aforementioned studies, high frequency and CFAE sites were identified using 
automated algorithms based on short (3 to 7 second) electrogram recordings collected 
sequentially using a roving catheter.  The validity of the resulting DF and CFAE maps 
is based on the assumption that these sites remain stable over time.  However, Habel et 
al. (2010) reported significant temporal and spatial variability of both high frequency 
and CFAE sites with sequential mapping failing to detect 93% and 36% of the high 
frequency and CFAE sites identified from simultaneous multielectrode recordings in the 
left atrium.   
Singh et al. (2010) investigated the use of ibutilide in guiding CFAE ablation and 
identifying critical AF sites in 11 patients with persistent AF.  They reported a 
significant reduction in left atrial CFAE burden after ibutilide administration and that 
AF termination was achieved in 10/11 (91%) patients following pulmonary vein 
isolation and ablation of residual CFAEs after ibutilide.  To our knowledge, the utility 
of flecainide in this context has not been studied.   
The aims of this study were: (1) To investigate the distribution and effectiveness of 
ablating stable high frequency (≥8Hz) and highly repetitive CFAE (interval confidence 
level ≥120) sites in patients with persistent AF identified using a 64-electrode contact 
mapping catheter (Constellation®, Boston Scientific Inc.) to record simultaneous 
electrograms from multiple sites in the left and right atria; (2) To assess the utility of 
administering intravenous flecainide during the procedure to reduce CFAE burden and 
identify sites critical to the maintenance of AF. 
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6.3 Methods 
6.3.1 Patient Recruitment and Ethical Approval 
This study was based on the same cohort of 12 patients described in Chapter 5 (Sections 
5.3.1 and 5.3.2). 
6.3.2 Electrophysiological Study 
Once femoral venous access had been achieved, a deflectable decapolar catheter was 
positioned in the coronary sinus (CS) under fluoroscopic guidance.  The distal poles of 
the CS catheter were positioned on the lateral aspect of the mitral valve ring, with 
proximal bipole CS9-10 just inside the ostium of the coronary sinus.  A single transseptal 
puncture was used to gain access to the left atrium and heparin anticoagulation was 
administered to maintain an activated clotting time >300 seconds.  Electroanatomical 
maps of both atria were created using a 3.5mm irrigated-tip bipolar ablation catheter 
(2mm inter-electrode spacing) and the EnSite Velocity™ cardiac mapping system (St. 
Jude Medical).  The Constellation® catheter was then deployed sequentially in the right 
and left atrium using a fixed curve (Heartspan™, Boston Scientific) and steerable 
sheath (Agilis™, St. Jude Medical) respectively.  One-minute intracardiac recordings 
were collected from one or two catheter positions in each atrium to ensure satisfactory 
coverage of the chamber.  If satisfactory contact with all areas of the atria could not be 
achieved using Constellation®, a bipolar ablation catheter was used to collect sequential 
1-minute recordings from these inadequately covered sites.  Intracardiac recordings 
were also collected simultaneously from the CS (steerable decapolar catheter) and 
sequentially from each of the pulmonary vein ostia (ablation catheter).  
6.3.3 Intracardiac Data Analysis 
Intracardiac data was collected using the same filter settings and electrode format 
described in Chapter 5 (Section 5.3.4). 
Dominant Frequency 
Power spectral density (PSD) of consecutive 10-second sections of bipolar electrograms 
was estimated by periodogram with rectangular window and frequency resolution of 
0.1Hz.  For each section, dominant frequency (DF) was identified as the intracardiac 
frequency with the highest power in the range 3-10Hz as previously defined (Raine et 
al., 2004 and 2005).  Sites with mean DF ≥8Hz from the one-minute recording were 
identified and tagged on the electroanatomical map.  The DF threshold of ≥8Hz was 
chosen in line with previous studies (Verma et al., 2011; Kumagai et al., 2013) 
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Complex Fractionated Atrial Electrograms 
We developed an automated CFAE detection algorithm to identify highly repetitive 
CFAE sites, which exhibited fractionated activity throughout the 1-minute recordings.  
This was based on the CFAE detection software embedded in the CARTO®3 mapping 
system (Biosense Webster) (Scherr et al., 2007) and is illustrated in Figure 6.1.  Firstly, 
bipolar electrogram peaks greater than or equal to ±0.05mV (green horizontal lines) are 
identified.  The peaks that fall within the voltage window of 0.05 to 0.15mV are tagged 
with black crosses, and those exceeding ±0.15mV (red horizontal lines) are tagged with 
red crosses.  Secondly, intervals between two successive peaks falling within the 
voltage window (0.05-0.15mV) were determined.  Thirdly, the number of intervals 
between 70 and 120ms during the 1-minute recording was determined as the interval 
confidence level (ICL).  Scherr et al. (2007) reported that an ICL≥5 (in a 2.5-second 
recording) was consistent with a highly repetitive CFAE.  As the focus of this study was 
on sites that exhibited fractionated activity throughout the 1-minute recording, we 
extrapolated their ICL recommendation and required an ICL≥120 (per 1-minute 
recording) to reflect a highly repetitive CFAE.  The highly repetitive CFAE sites 
identified were manually verified by analysis of the bipolar electrograms and tagged on 
the electroanatomical map. 
6.3.4 Catheter Ablation 
All patients underwent PVI by wide-area circumferential ablation, which was confirmed 
using standard pacing manoeuvres.  After PVI, 11/12 patients remained in AF and 
received intravenous flecainide (2mg/kg up to maximum dose of 150mg) as per study 
protocol (Figure 6.2).  The Constellation® catheter was then redeployed and additional 
1-minute recordings were collected from the original catheter positions in each atria.  
Sites with mean DF ≥8Hz and/or highly repetitive CFAE activity after flecainide were 
tagged on the electroanatomical map and targeted with ablation.  If sinus rhythm was 
not restored, ablation was performed at the high frequency and highly repetitive CFAE 
sites identified prior to flecainide administration.  The procedure was curtailed when all 
identified high frequency and highly repetitive CFAE sites had been ablated.  Patients 
who did not revert to sinus rhythm during ablation underwent electrical cardioversion at 
the end of the procedure. 
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6.3.5 Clinical Outcome 
Clinical outcome was assessed 12 months after ablation by symptom review, 12-lead 
ECG, and 72-hour Holter recordings.  AF recurrence was defined as the presence of 
arrhythmia symptoms with documented AF on a 12-lead ECG and/or AF episodes >30 
seconds on Holter monitoring.  In line with other studies, AF recurrences in the 3-month 
blanking period after ablation were excluded from the analysis. 
6.4 Results 
Characteristics of the 12 consecutive patients recruited to the study are shown in Table 
5.2.  Ten of the 12 patients had longstanding persistent AF (AF episode duration ≥1 
year (Camm et al., 2010)).  60mm Constellation® catheters (5mm inter-electrode 
spacing) were used in eight patients and 48mm catheters (4mm inter-electrode spacing) 
in the remaining four patients.  All patients required two Constellation® catheter 
positions in the left atrium and 7/12 patients required two catheter positions in the right 
atrium.  The number of Constellation® catheter bipoles with electrograms suitable for 
analysis (i.e. containing atrial activity without significant artefact or noise) was 
2034/2688 (76%) – right atrium (RA) 1179/1344 (88%) vs. left atrium (LA) 855/1344 
(64%).  Mean procedure duration was 219 ± 31 minutes.    
6.4.1 High Frequency Site Distribution 
High frequency sites (DF≥8Hz) were identified in 4/12 patients (33%) with a similar 
number in both atria: RA (n=32) and LA (n=31) (Figure 6.3).  In the right atrium, the 
majority of high frequency sites were located in the crista terminalis (n=13) and right 
atrial appendage (n=10).  In the left atrium, high frequency sites were more evenly 
distributed between the left sided pulmonary veins, left atrial appendage, roof and 
posterior wall. 
6.4.2 Highly Repetitive CFAE Distribution 
Highly repetitive CFAEs (ICL≥120) were observed in all 12 patients and were more 
commonly found in the right (n=377) than the left atrium (n=296) (Figure 6.4).  The 16 
CFAEs in the left upper pulmonary vein and 28 in the left lower pulmonary vein were 
successfully abolished with PVI leaving 252 CFAEs in the left atrium prior to 
flecainide.  In the right atrium, the commonest locations for highly repetitive CFAEs 
were the anterior wall (n=75), superior vena cava (n=62) and crista terminalis (n=61).  
In the left atrium, the majority of highly repetitive CFAEs were located in the posterior 
wall (n=76), anterior wall (n=46) and roof (n=42). 
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6.4.3 Utility of Flecainide in identifying critical AF sites 
Intravenous flecainide resulted in a general reduction in atrial frequencies to between 3 
and 4 Hz; therefore, no high frequency (DF≥8Hz) sites were observed in either atrium 
after flecainide administration.  In addition, there was a significant reduction in the 
number of highly repetitive CFAEs after flecainide: RA 58 (85% reduction) and LA 54 
(79% reduction) (Figure 6.5).  In the right atrium, the commonest locations for highly 
repetitive CFAEs after flecainide were the superior vena cava (n=18) and right atrial 
appendage (n=15).  In the left atrium, highly repetitive CFAEs were most commonly 
found in the left atrial floor (n=16) and appendage (n=11).  None of the patients 
cardioverted to sinus rhythm during high frequency and/or highly repetitive CFAE site 
ablation.   
6.4.4 Twelve Month Outcome 
Of the 12 patients studied, three (25%) maintained sinus rhythm at 12-month follow-up 
without further intervention.  Two patients developed atypical left atrial flutter 
successfully treated by a second ablation procedure.  The remaining seven patients 
(58%) experienced recurrent AF and six underwent a second ablation procedure.  All 
six patients had evidence of pulmonary vein reconnection and had their pulmonary 
veins re-isolated.  Additional linear lesions were constructed to consolidate the previous 
high frequency ± CFAE ablation.  The remaining patient had minimal symptoms despite 
AF recurrence and opted for a rate control strategy. 
6.5 Discussion 
The main findings of this study are: (1) Multipolar contact mapping guided ablation of 
temporally stable high frequency (≥8Hz) and CFAE sites does not improve 12-month 
outcomes in patients with persistent AF; (2) Flecainide significantly reduces CFAE 
burden but does not identify sites critical to the maintenance of AF; (3) Stable high 
frequency and highly repetitive CFAE sites are distributed throughout both atria in 
patients with persistent AF with highly repetitive CFAEs more commonly identified; 
(4) The primary limitation of the Constellation® catheter is its inability to provide 
comprehensive coverage of particularly the left atrium from one position. 
6.5.1 High Frequency and Highly Repetitive CFAE Site Distribution 
In this study, high frequency sites in the right atrium were most commonly identified in 
the crista terminalis and right atrial appendage.  Okumura et al. (2012) identified high 
frequency and CFAE sites in the right atrium in 58% and 68% of patients respectively 
who remained in AF after PVI, but did not report their distribution within the right 
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atrium.  In agreement with previous studies (Okumura et al., 2012; Nakahara et al., 
2013), high frequency sites in the left atrium were more evenly distributed between the 
left sided pulmonary veins, left atrial appendage, roof and posterior wall.  Interestingly, 
more highly repetitive CFAEs were found in the right than the left atrium in this study, 
which is in contrast to Solheim et al. (2010) who, aside from the right atrial septum, 
observed significantly fewer CFAEs in the right compared to the left atrium.  The 
differing results may be explained by differences in data collection and CFAE analysis.  
Solheim et al. (2010) used a 3.5mm irrigated ablation catheter to record sequential 8-
second electrograms from multiple atrial sites analysed using the CFAE mapping 
software in the EnSite™ NavX™ system (St. Jude Medical); whereas, we used 
Constellation® to collect simultaneous multipoint recordings from one or two positions 
in each atria and identified highly repetitive CFAEs which exhibited fractionated 
activity throughout the one-minute recordings using customised software.  In our study, 
highly repetitive right atrial CFAEs were most commonly found in the anterior wall, 
superior vena cava and crista terminalis; however, CFAEs were identified in all sections 
of the right atrium (Figure 6.4).  Chen et al. (2013) also observed CFAEs throughout the 
right atrium but reported that the commonest sites for conversion to atrial tachycardia or 
sinus rhythm were the crista terminalis, followed by the right atrial appendage and 
septum.  In agreement with previous studies (Nakahara et al., 2013; Solheim et al., 
2010), the majority of highly repetitive left atrial CFAEs were located in the posterior 
wall, anterior wall and roof in this study. 
6.5.2 Utility of Flecainide in identifying critical AF sites 
The number of highly repetitive CFAEs reduced significantly after flecainide 
administration, although, none of the patients cardioverted to sinus rhythm during 
ablation of these sites.  Flecainide does not appear to be useful therefore in identifying 
sites critical to the maintenance of AF.  This is in contrast to the aforementioned study 
of Singh et al. (2010) who reported AF termination in 91% of patients after PVI and 
ablation of CFAEs remaining after ibutilide.  The differing results could be explained 
by the different pharmacological mechanism of action (Class 3 (ibutilide) vs. Class 1C 
(flecainide)) and the low dose of ibutilide (0.25mg) used compared to our higher 
relative dose of flecainide (2mg/kg).    
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6.5.3 Effectiveness of High-Frequency and CFAE Site Ablation 
Of the 12 patients studied, five (42%) were free of AF at 12-month follow up.  This 
included two patients who developed atypical left atrial flutter successfully treated by a 
second ablation procedure.  Our results are comparable to the 47% mean success rate 
for substrate ablation techniques reported by Brooks et al. (2010) in their systematic 
review.  In agreement with Kumagai et al. (2013), none of the patients cardioverted to 
sinus rhythm during high frequency or CFAE ablation, despite focusing on sites that 
exhibited high frequency and/or fractionated activity throughout the one-minute 
recordings.  In their study which included 27 patients with persistent AF, only 1 patient 
cardioverted to sinus rhythm during a stepwise ablation protocol including PVI, 
hierarchical high frequency site (DF>8Hz) and continuous CFAE (fractionated interval 
<50ms) ablation and 13/27 (48%) patients were free of AF without antiarrhythmic drugs 
at 12-month follow up.  Our results support the view that CFAE sites are not critical to 
the maintenance of AF and are more likely explained by wavefront collision and 
breakout in areas of tissue heterogeneity or at the boundaries of fixed high-frequency 
rotors (Oral et al., 2008; Lin et al., 2010).   
Regarding high frequency site ablation, the use of a DF threshold of 8Hz significantly 
reduces the number of high frequency sites identified as sites with DF≥8Hz were only 
found in 4/12 (33%) patients in this study (Chapter 5).  Interestingly, the two other 
studies in which DF sites ≥8Hz were also targeted with ablation reported low AF 
termination rates (Verma et al., 2011; Kumagai et al., 2013); whereas, Atienza et al. 
(2009) reported that ablation of sites with the highest frequency (DF≥20% higher than 
surrounding points) in individual patients was associated with a higher likelihood of 
maintaining sinus rhythm at 12-month follow up. 
6.5.4 Inter-Atrial Frequency Gradients and their Relationship to Ablation Outcome 
Of the five patients who maintained sinus rhythm 12-months after ablation, three had a 
‘left-to-right’ atrial frequency gradient, one had a ‘right-to-left’ atrial frequency gradient 
and the remaining patient had no atrial frequency gradient (Chapter 5).  All patients 
with inter-atrial frequency gradients received CFAE ± high frequency site ablation in 
the dominant atrium.  On first inspection, these results appear disappointing with 
respect to the role of high frequency sites in the right atrium maintaining AF in patients 
with a right-to-left atrial frequency gradient.  However, in the remaining two patients 
with right-to-left atrial frequency gradients, one had a right atrial DFMAX <8Hz which 
was therefore not ablated and the other had a right atrial DFMAX ≥8Hz adjacent to the 
sinus node which was not ablated due to the risk of significant complication.   
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Of the four patients who underwent ablation of high frequency sites (DF ≥8Hz), three 
maintained sinus rhythm 12-months after ablation and the remaining patient had high 
frequency sites throughout both atria with no clear DFMAX responsible for maintaining 
the arrhythmia.  These results support the need for further studies investigating the role 
of high frequency site ablation targeting DFMAX of the individual patient rather than an 
arbitrary cutoff of ≥8Hz. 
6.6 Limitations 
Firstly, the findings are based on only the 12 patients studied.  Secondly, only one size 
of Constellation® catheter was used per patient, which meant that contact could not be 
optimised to the individual dimensions of either atrium in some cases.  Thirdly, data 
was collected sequentially from one or two catheter positions in each atrium, which 
meant a compromise between maximising the number of atrial sites recorded and the 
degree in which all electrograms were recorded simultaneously.  However, we do not 
believe that this significantly affected our findings.  The primary limitation in this 
methodology is the inability of the Constellation® catheter to provide comprehensive 
coverage of particularly the left atrium from one position despite deployment via a 
flexible sheath.  The left atrial floor and septum were the most difficult areas to achieve 
contact with using Constellation® and bipolar electrograms had to be collected from 
these sites using the ablation catheter in several patients.  This highlights the difficulty 
in developing a multipolar mapping catheter with adjustable dimensions and 
manoeuvrability to allow tissue contact and coverage from one position.  Finally, due to 
a lack of parallel processing capability and consequent real-time analysis, the high 
frequency ablation strategy targeted sites with DF ≥8Hz rather than the DFMAX of the 
individual patient.  This is likely to have underestimated the effectiveness of high 
frequency site ablation and warrants further study as detailed above. 
6.7 Conclusions 
Highly repetitive CFAEs are distributed throughout both atria in patients with persistent 
AF.  High frequency (≥8Hz) sites are also found in both atria but are less frequently 
observed.  Flecainide administration significantly reduces CFAE burden but does not 
help identify sites critical to the maintenance of AF.  None of the patients cardioverted 
to sinus rhythm during high frequency or CFAE ablation and 12-month outcome was 
comparable to other substrate ablation techniques.
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 Figure 6.1: CFAE Detection Algorithm.  Each panel illustrates a 5-second section of atrial electrogram recorded using the Constellation® catheter.  
The top panel contains complex fractionated activity throughout the recording as illustrated by the solid black lines at the top of the panel.  The bottom 
panel does not contain any complex fractionated activity and therefore, there are no solid black lines above the recording.  See text for highly repetitive 
CFAE detection criteria. 
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Figure 6.2: Study Protocol. SR = sinus rhythm.
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Figure 6.3: Distribution of High Frequency Sites (DF≥8Hz).   The number of high frequency sites identified in each atrial location is shown.  CT = 
crista terminalis; IVC = inferior vena cava; LAA = left atrial appendage; LAT = lateral left atrium; LLPV = left lower pulmonary vein; LUPV = left 
upper pulmonary vein; RAA = right atrial appendage; RLPV = right lower pulmonary vein; RUPV = right upper pulmonary vein; SEP = septum; SVC 
= superior vena cava. 
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Figure 6.4: Distribution of Highly Repetitive CFAEs (ICL≥120).  The number of highly repetitive CFAEs identified in each atrial location is 
shown.  Abbreviations as for Figure 6.3. 
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Figure 6.5: Distribution of Highly Repetitive CFAEs after Flecainide.  The number of highly repetitive CFAEs identified in each atrial location 
after flecainide administration is shown.  Abbreviations as for Figure 6.3.
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Chapter 7.  Final Discussion 
The unifying aim of this thesis was to investigate whether we could predict and improve 
clinical outcome following ablation in patients with AF using surface AF waveform 
analysis and multipolar contact mapping respectively.  The results from Chapter 3 show 
that we can accurately predict acute and more importantly 12-month outcome following 
ablation using a combination of clinical and surface AF waveform parameters.  
Paroxysmal AF, male gender and fibrillatory wave amplitude in posterior ECG lead V9 
were independent predictors of sinus rhythm maintenance 12-months after ablation.  
Fibrillatory wave amplitude in lead V9 has not been previously studied and our results 
highlight the benefit of analysing posterior ECG leads in this context.  The utility of 
surface AF waveform analysis in predicting 12-month outcome following ablation is 
particularly relevant in the selection of patients for ablation of persistent AF as it could 
be used to guide the decision regarding rhythm vs. rate control at the initial outpatient 
consultation.  Patients with a low likelihood of maintaining sinus rhythm longer term 
could be recommended a rate control strategy and so avoid the need for multiple, 
ultimately unsuccessful, ablation procedures with their associated risks.  Future research 
should focus on prospectively testing the multivariate risk scores derived from this 
study by comparing predicted versus observed outcome 12 months after ablation in a 
new cohort of patients with persistent AF.  An important precursor to this is to test the 
efficacy of extracting AF waveform parameters from Holter ECG recordings (including 
posterior leads) prior to the initial outpatient review. 
Chapter 4 highlights the importance of maintaining sinus rhythm following ablation to 
improve quality of life and AF symptoms.  Similar improvements in quality of life were 
observed in patients with paroxysmal and persistent AF, which is an important 
observation in the current climate of NHS Commissioning as it supports the benefits of 
ablation for patients with persistent AF.  Further research in this area should focus on 
assessing quality of life and AF symptoms 12-months after ablation and compare 
rhythm vs. rate control strategies in patients with persistent AF using AF-specific 
quality of life scales. 
Chapters 5 and 6 examine the role of multipolar contact mapping in identifying inter-
atrial frequency gradients and facilitating high frequency and highly repetitive CFAE 
ablation in patients with persistent AF.  A quarter of the patients studied had right-to-
left atrial frequency gradients, which implies that their arrhythmia is maintained by high 
frequency sources in the right atrium.   
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The presence of right-to-left atrial frequency gradients and the stability of high 
frequency sources over a one-minute period have not been previously reported.  Highly 
repetitive CFAEs were distributed throughout both atria in all of the patients studied.  
High frequency (DF ≥8Hz) sites were also found in both atria but were only identified 
in a third of patients.  None of the patients cardioverted to sinus rhythm during high 
frequency or CFAE ablation and 12-month outcome was comparable to other substrate 
ablation techniques in this patient cohort (42% success after a single AF ablation 
procedure). 
The results from Chapters 5 and 6 are interesting for a number of reasons.  Firstly, they 
add support to the growing body of evidence that CFAE sites are not critical to the 
maintenance of AF and are more likely explained by wavefront collision and breakout 
in areas of tissue heterogeneity or at the boundaries of fixed high-frequency rotors.  
Secondly, of the four patients who underwent ablation of high frequency sites (DF 
≥8Hz), three maintained sinus rhythm 12-months after ablation and the remaining 
patient had high frequency sites throughout both atria with no clear site responsible for 
maintaining the arrhythmia.  These results support the role of high frequency site 
ablation and the need for further studies targeting DFMAX in the individual patient rather 
than an arbitrary cutoff of ≥8Hz.  Thirdly, this study highlighted an important technical 
limitation of the Constellation® catheter which is its inability to provide comprehensive 
coverage of particularly the left atrium from one position.  This prevents collection of 
truly simultaneous recordings from both atria, which, in my opinion, is the crucial next 
step in developing our understanding of the pathophysiology of AF and refining the 
ablation strategy in patients with persistent AF.  Development of a multipolar contact 
mapping catheter with adjustable dimensions and improved manoeuvrability to enable 
comprehensive coverage of each atrium from one position is a key component needed 
for future AF research. 
I would like to close by discussing my thoughts with respect to AF ablation.  When I 
started this MD research project, I was a firm believer of pulmonary vein isolation 
(PVI) alone for patients with paroxysmal AF and PVI plus left atrial substrate ablation 
in patients with persistent AF as a first ablation procedure.  However, the results of 
Chapters 3 and 6 together with the recently published STAR AF II trial (Verma et al., 
2015), which showed no benefit of adding CFAE and linear left atrial ablation to PVI as 
a first ablation procedure in patients with persistent AF, have changed my opinion.   
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I now advocate PVI alone as a first procedure for all patients with AF (irrespective of 
AF type) with the Arctic Front Advance® cryoballoon being my ablation technology of 
choice on account of its high rate of durable pulmonary vein isolation and lower risk of 
complications.  I would then consider linear left atrial ablation in addition to re-isolation 
of the pulmonary veins (when required) for patients with recurrent AF.  This is based on 
the meta analysis by Wynn et al. (2014) who reported that patients with persistent AF 
who underwent PVI and limited linear left atrial ablation had a significantly lower 
incidence of AF recurrence compared to other ablation strategies.  In this context, the 
efficacy of high frequency site ablation focused on DFMAX in the individual patient 
warrants further study as previously discussed.  I would like to conclude by stressing 
the importance of tackling the risk factors for AF including obesity, hypertension, 
diabetes mellitus, hyperlipidaemia and obstructive sleep apnoea to further reduce AF 
burden and improve the likelihood of maintaining sinus rhythm after ablation in line 
with the results of the ARREST-AF study (Pathak et al., 2014).  
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